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Abstract 
Parkinson’s Disease is one of the most frequent human 
neurodegenerations. Motor symptoms of Parkinson’s disease are the 
consequence of the destruction of nervous cells in the substantia nigra 
(SN). For many years it has been believed that the degeneration of 
nervous cells in SN in Parkinson’s disease is related to an important 
increase in the concentration of iron. This excess of iron, which may 
initiate Fenton reaction, may be the cause of the oxidative stress 
leading to the death of nervous cells in PD. However, the mechanisms 
involved in iron accumulation remain unclear.  Transferrin Receptor type 
2 (TfR2) is a protein expressed on cell membrane end involved in the 
cellular iron uptake. It is not ubiquitously expressed like Transferrin 
Receptor type 1 but it is especially expressed in several tissues such as  
liver and recently, it has been discovered to be strongly involved in 
neuronal iron uptake in neurodegenerative disease. This suggests its 
potential involvement in the iron overload in the Substantia Nigra, a 
commonly observed phenomenon in Parkinson’s Disease. The mRNA 
encoding for TfR2 does not contain the Iron Responsive Element (IRE) 
in its 3’ UTR, so its regulation is surely non mediated by Iron Regulative 
Proteins (IRPs). Another gene/protein strongly involved in iron 
metabolism but not regulated by intracellular iron concentrations via 
IRPs is DMT1 -IRE. It is a divalent metal transporter so it could be 
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involved in PD iron excess. The aim of this thesis was to evaluate the 
expression of both the previously mentioned gene/proteins in a 
commonly used in vitro model of PD composed of SH-SY5Y treated with 
MPP+ (1-methyl-4-phenylpyridinium), since they are not regulated by 
IRPs, and to answer the question: “Is supposable a regulation 
microRNA-mediated?”.  
The expression of DMT1 –IRE and TfR2 was evaluated at both mRNA 
and protein level in treated cells after 0, 24 and 48 hours from 
treatment with MPP+. For both genes/proteins an increase in the 
expression was found in treated cells.  
MicroRNA-221 was selected among two potential candidate microRNAs, 
restricted from a list of them resulted by bioinformatics prediction of 
microRNAs targeting the 3’UTR of TfR2. Using luciferase assay it was 
demonstrated the real ability of microRNA 221 in TfR2 3’UTR binding.  
The function of microRNA-221 was verified in the chosen PD in vitro 
model. A similar experimental plan was used to verify the action of 
microRNA-Let-7d on the regulation of DMT1 –IRE isoform in the same  
PD cellular model.  
In this thesis it is demonstrated that  SH-SY5Y cells treated with MPP+ 
show an increase in the expression of TfR2 and DMT1 -IRE respect to 
control cells (after 24 and 48 hours from treatment); at the same time, 
a significant reduction in the expression of microRNA-221 and of 
microRNA-Let-7d occurs. The over-expression of microRNA-221 in 
treated cells causes a decrease in the expression of TfR2, while when 
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cells are transfected with a vector containing microRNA-221 mutated in 
the binding site for the seed region, this microRNA loses the ability to 
bind the 3’UTR of TfR2 and its expression is completely restored. On the 
other hand, the over-expression of microRNA-Let-7d in treated cells 
causes a decrease in the expression of DMT1 -IRE, while cells 
transfected with a vector containing a mutated form of microRNA-Let-
7d that loses the ability to bind the 3’UTR of TfR2, show a TfR2 
expression restored and comparable with the expression in untreated 
cells.  
These results suggest that microRNA-221 is involved in the iron 
metabolism fine regulation, acting specifically on TfR2 expression in the 
used Parkinson’s Disease in vitro model and that microRNA-Let-7d is 
able to regulate the expression of DMT1 –IRE, a transporter that could 
be involved in the iron over-load in PD. Further studies could show the 
way forward to the therapeutic targeting of this pathway which could be 
directed to the down-regulation of the expression of both TfR2 and 
DMT1 -IRE in the dopaminergic neurons of the Substantia Nigra in PD. 
This findings could be important to obviate the need for the systemic 
ferrochelant therapy to which patients are often subjected as adjuvant 
treatment together with the specific therapy for Parkinson’s Disease.
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Introduction 
 
1. Parkinson’s disease 
Parkinson’s disease (also known as Parkinson’s, Parkinson Disease or 
PD) is a degenerative disorder of the central nervous system (CNS) that 
often impairs the sufferer’s motor skills, speech, and other functions 
(Jankovic J, 2008). Parkinson’s disease belongs to a group of conditions 
called movement disorders. It is characterized by muscle rigidity, 
tremor, a slowing of physical movement (bradykinesia) and loss of a 
physical movement (akinesia) in extreme cases. The primary symptoms 
are the results of decreased stimulation of the motor cortex  by the 
basal ganglia, normally caused by the insufficient formation and action 
of the dopamine, which is produced in the dopaminergic neurons of the 
brain (specifically the substantia nigra, SN). Secondary symptoms may 
include high level cognitive disfunction and subtle language problems. 
PD is both chronic and progressive.  
PD is the most common cause of chronic progressive parkinsonism, a 
term which refers to the syndrome of tremor, rigidity, bradykinesia and 
postural instability. PD is also called “primary parkinsonism” or 
“idiopathic PD” (classically meaning having no known causes). While 
many forms of parkinsonism are idiophatic, “secondary” cases may 
result from toxicity most notably of drugs, head trauma, or other 
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medical disorders. The disease is named  after English apothecary 
James Parkinson, who made a detailed description of the disease in his 
essay: “An Essay on the Shaking Palsy” (1987). 
 
1.1 Classification 
The term parkinsonism is used for a motor syndrome whose main 
symptoms are tremor at rest, stiffness, slowing of movement and 
postural instability. Parkinsonian syndromes can be divided into four 
subtypes according to their origin: primary or idiopathic, secondary or 
acquired, hereditary parkinsonism, and parkinson plus syndromes or 
multiple system degeneration (Jankovic J, 2008). Parkinson's disease is 
the most common form of parkinsonism and is usually defined as 
"primary" parkinsonism, meaning parkinsonism with no external 
identifiable cause (Samii A et al. 2004; Schrag A et al. 2007). In recent 
years several genes that are directly related to some cases of 
Parkinson's disease have been discovered. As much as this can go 
against the definition of Parkinson's disease as an idiopathic illness, 
genetic parkinsonism disorders with a similar clinical course to PD are 
generally included under the Parkinson's disease label. The terms 
"familial Parkinson's disease" and "sporadic Parkinson's disease" can be 
used to differentiate genetic from truly idiopathic forms of the disease 
(Davie CA, 2008).  
PD is usually classified as a movement disorder, although it also gives 
rise to several non-motor types of symptoms such as sensory deficits 
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(Barnett-Cowan M, 2010), cognitive difficulties or sleep problems. 
Parkinson plus diseases are primary parkinsonisms which present 
additional features. They include multiple system atrophy, progressive 
supranuclear palsy, corticobasal degeneration and dementia with Lewy 
bodies. In terms of pathophysiology, PD is considered a synucleinopathy 
due to an abnormal accumulation of alpha-synuclein protein in the brain 
in the form of Lewy bodies, as opposed to other diseases such as 
Alzheimer's disease where the brain accumulates tau protein in the form 
of neurofibrillary tangles (Galpern WR et al., 2006). Nevertheless, there 
is clinical and pathological overlap between tauopathies and 
synucleinopathies. The most typical symptom of Alzheimer's disease, 
dementia, occurs in advanced stages of PD, while it is common to find 
neurofibrillary tangles in brains affected by PD (Galpern WR et al., 
2006). Dementia with Lewy bodies (DLB) is another synucleinopathy 
that has similarities with PD, and especially with the subset of PD cases 
with dementia. However the relationship between PD and DLB is 
complex and still has to be clarified (Aarsland D et al., 2009). They may 
represent parts of a continuum or they may be separate diseases 
(Aarsland D et al., 2009).  
 
1.2 Signs and Symptoms 
Motor 
Four motor symptoms are considered cardinal in PD: tremor, rigidity, 
slowness of movement, and postural instability (Jankovic J, 2008). 
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• Tremor is the most apparent and well-known symptom. It is the 
most common; though around 30% of individuals with PD do not have 
tremor at disease onset, most develop it as the disease progresses. It is 
usually a rest tremor: maximal when the limb is at rest and 
disappearing with voluntary movement and sleep. It affects to a greater 
extent the most distal part of the limb and at onset typically appears in 
only a single arm or leg, becoming bilateral later (Jancovic J, 2008).  
• Bradykinesia is another characteristic feature of PD, and is 
associated with difficulties along the whole course of the movement 
process, from planning to initiation and finally execution of a 
movement. Performance of sequential and simultaneous movement is 
hindered (Jancovic J, 2008). Bradykinesia is the most disabling 
symptom in the early stages of the disease (Samii A et al., 2004). 
• Rigidity is stiffness and resistance to limb movement caused by 
increased muscle tone, an excessive and continuous contraction of 
muscles. In parkinsonism the rigidity can be uniform (lead-pipe rigidity) 
or ratchety (cogwheel rigidity) (Banich MT et al., 2011; Samii A et al., 
2004; Jancovic J, 2008). The combination of tremor and increased tone 
is considered to be at the origin of cogwheel rigidity. Rigidity may be 
associated with joint pain; such pain being a frequent initial 
manifestation of the disease (Jancovic J, 2008). In early stages of 
Parkinson's disease, rigidity is often asymmetrical and it tends to affect 
the neck and shoulder muscles prior to the muscles of the face and 
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extremities. With the progression of the disease, rigidity typically affects 
the whole body and reduces the ability to move. 
• Postural instability is typical in the late stages of the disease, 
leading to impaired balance and frequent falls, and secondarily to bone 
fractures. Instability is often absent in the initial stages, especially in 
younger people (Samii A et al., 2004; Jancovic J, 2008). Up to 40% of 
the patients may experience falls and around 10% may have falls 
weekly, with number of falls being related to the severity of PD. 
Neuropsychiatric 
Parkinson's disease can cause neuropsychiatric disturbances which can 
range from mild to severe. This includes disorders of speech, cognition, 
mood, behaviour, and thought. Cognitive disturbances can occur in the 
initial stages of the disease and sometimes prior to diagnosis, and 
increase in prevalence with duration of the disease (Jancovic J, 2008; 
Caballol N et al., 2007). The most common cognitive deficit in affected 
individuals is executive dysfunction, which can include problems with 
planning, cognitive flexibility, abstract thinking, rule acquisition, 
initiating appropriate actions and inhibiting inappropriate actions, and 
selecting relevant sensory information. Fluctuations in attention and 
slowed cognitive speed are among other cognitive difficulties. Memory is 
affected, specifically in recalling learned information. Nevertheless, 
improvement appears when recall is aided by cues. Visuospatial 
difficulties are also part of the disease (Caballol N et al., 2007).  
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A person with PD has two to six times the risk of suffering dementia 
compared to the general population. The prevalence of dementia 
increases with duration of the disease. Behavior and mood alterations 
are more common in PD without cognitive impairment than in the 
general population, and are usually present in PD with dementia. The 
most frequent mood difficulties are depression, apathy and anxiety. 
Psychotic symptoms, hallucinations or delusions occur in 4% of 
patients, and it is assumed that the main precipitant of psychotic 
phenomena in Parkinson’s disease is dopaminergic excess secondary to 
treatment; it therefore becomes more common with increasing age and 
levodopa intake (Friedman JH, 2010).  
Others 
In addition to cognitive and motor symptoms, PD can impair other body 
functions. Sleep problems are a feature of the disease. Symptoms can 
manifest in daytime drowsiness, disturbances in REM sleep, or 
insomnia. Alterations in the autonomic nervous system can lead to 
orthostatic hypotension (low blood pressure upon standing), oily skin 
and excessive sweating, urinary incontinence and altered sexual 
function (Jancovic J, 2008). Constipation and gastric dysmotility can be 
severe enough to cause discomfort and even endanger health 
(Barichella M et al., 2009). PD is related to several eye and vision 
abnormalities (Armstrong RA, 2008). Changes in perception may 
include an impaired sense of smell, sensation of pain and paresthesia 
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(skin tingling and numbness). All of these symptoms can occur years 
before diagnosis of the disease (Jancovic J, 2008).  
 
1.3 Causes 
To date, despite decades of intensive study, the causes of PD remain 
unknown. Many evidences show that the disease is caused by a 
combination of genetic and environmental factors, which may vary from 
person to person. 
In some people, genetic factors may play a role; in others, illness, an 
environmental toxin or other event may contribute to PD. Aging is 
surely an important risk factor. With a prevalence of approximately 1% 
at age 65, which rises to nearly 5% by age 85, PD is the second most 
common neurodegenerative disorder after Alzheimer’s disease (de Lau 
LML et al., 2006; Van Den Eeden SK et al., 2003). The chemical or 
genetic trigger that starts the cell death process in dopamine neurons is 
the subject of intense scientific study. Generically we can divide 
Parkinson’s causes in two different groups: 
- Genetic causes 
PD traditionally has been considered a non-genetic disorder however at 
least between 5 and 10% of patients are now known to have monogenic 
forms of the disease (Lesage S et al., 2009). Other genes act as a risk 
factor for sporadic cases of the disease. To date, a number of specific 
genetic mutations causing PD have been discovered. Linkage studies 
and positional cloning strategies have identified mutations in a number 
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of genes that cause several monogenic autosomal-dominant or 
autosomal-recessive forms of the disorder. Mutations in at least five 
genes have been firmly linked to either dominant or recessive early-
onset familial forms of PD. Additional loci segregating with inherited PD 
have been identified and the causative genes await identification.  
Known “PD genes” are α-synuclein, parkin, DJ-1, PTEN-induced kinase-
1 (PINK1) and leucine-rich repeat kinase 2 (LRRK2)/Dardarin. Mutations 
in these genes result in cellular alterations that are similar to those seen 
in sporadic PD and may include impaired mitochondrial function and 
dynamics, increased oxidative stress (sensitivity) and abnormal protein 
aggregation (Figure 1). 
 
Figure 1. Genes involved in Parkinson’s Disease. 
 
Although most of these Mendelian forms of Parkinson’s disease are rare, 
whole-genome association studies have more recently provided 
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convincing evidence that low-penetrance variants in at least some of 
these, but also in several other genes, play a direct role in the etiology 
of the common sporadic disease as well (Simon-Sanchez J et al., 2009). 
In Table 1 is reported a list of the most important genes involved in PD. 
The role of SNCA gene (encoding for alpha-synuclein) is central in the 
pathophysiology of PD, since alpha-synuclein protein is the main 
component of Lewy bodies, which are present in this and other 
diseases. Missence mutation of the gene and duplications or triplications 
of the locus containing it have been found in different groups of familial 
PD (Lasage S et al., 2009). 
 
Table 1. List of the most important genes involved in PD, chromosome position and 
tranmission. 
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- Toxins 
Findings on environmental predisposing to the disease have remained in 
general incomnsistent. Most replicated relationship are in increased risk 
of PD in those living in rural environments and those expose to 
pesticides and a reduced risk in smokers (Davie CA, 2008). In a 
longitudinal investigation, individuals who were exposed to pesticides 
had a 70% higher incidence of PD than individuals who were not 
exposed (Ascherio A et al., 2006). 
 
1.4 Hint of pathophysiology of Parkinson’s Disease  
Overview 
The Basal Ganglia is an important group of structures in the Central 
Nervous System that function in the regulation and control of 
movement. These structures are nuclei that are interconnected with 
each other and with other cortical and subcortical structures. They use 
two separate pathways to send input received from the Sensorimotor 
Cortex through the various structures that make up the Basal Ganglia 
and back out to the Motor Cortex. They do this through the use of the 
neurotransmitters Glutamate, GABA, Enkephalin, Substance P, 
Acetylcholine, and Dopamine. The direct pathway results in a facilitation 
of a desired movement and the indirect pathway results in an inhibition 
of undesired movement. Dysfunction of these Basal Ganglia structures 
and pathways results in the movement disorder known as Parkinson's 
disease. 
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Functional Anatomical Review 
The Basal Ganglia are a somatotopically organized grouping of nuclei 
located deep to the cortex that surround the Thalamus and are superior 
to the brainstem. They function in the processing of information in 
regards to the execution of movement. Its constituent parts are the 
Caudate, Putamen, Globus Pallidus, Subthalamic Nucleus (STN), and 
Substantia Nigra. The Caudate and Putamen make up the Striatum and 
are the main receptors for input to the Basal Ganglia from other areas. 
The Corpus Striatum is the same as the Striatum but it includes the 
Globus Pallidus, and the Lenticular Nucleus consists of the Putamen and 
Globus Pallidus. The Globus Pallidus has both an internal (GPi) and an 
external segment (GPe). The Substantia Nigra also has two parts -- the 
pars compacta (SNc) and pars reticulata (SNr). The GPe, STN, and SNc 
are involved in the internal processing within the Basal Ganglia 
pathways. The two main output nuclei are the SNr and GPi. 
The Caudate is located most superior of the nuclei. It is also the largest 
forming the anterior portion of the Striatum and stretching back over 
and around the Lenticular Nucleus. Inferior and lateral to that is the 
Putamen, then the Globus Pallidus is internal to that. The Subthalamic 
Nucleus is located beneath the Thalamus as you probably inferred from 
its name. The Substantia Nigra is located in the Midbrain near the 
cerebral peduncles. There are two pathways within the Basal Ganglia: 
the direct pathway and the indirect pathway. The direct pathway 
facilitates intended movements and the indirect pathway inhibits 
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unintended movements. The direct pathway begins with the Striatum 
being excited by the Cortex. The Striatum then inhibits the internal 
segment of the Globus Pallidus and the Substantia Nigra pars reticulata 
using the neurotransmitters GABA or Substance P (Sub P). When these 
structures are inhibited they cannot inhibit the Thalamus rendering it 
free to fire and send excitatory input up to the Cortex, which facilitates 
movement. The indirect pathway begins with the Striatum being excited 
by the Cortex (just like the direct pathway). Then Striatal neurons send 
inhibitory input to the external segment of the Globus Pallidus using the 
neurotransmitters GABA or Enkephalin (enk). The Globus Pallidus 
external segment usually sends inhibitory input to the Subthalamic 
Nucleus using GABA, but if it is inhibited by the Striatum then it is 
unable to inhibit the Subthalamic nucleus leaving it free to fire. The 
Subthalamic Nucleus being uninhibited sends the only purely excitatory 
input within the Basal Ganglia pathways to the Globus Pallidus internal 
segment and the Substantia Nigra pars reticulata. These structures then 
inhibit the Ventral lateral nucleus (VL) and  Ventral anterior nucleus 
(VA) of the Thalamus making it unable to send excitatory input to the 
Cortex and thus indirectly inhibiting the Motor Cortices, which inhibits 
movement. The Substantia Nigra pars compact plays a key role in the 
balance of direct versus indirect pathway. If functioning correctly the 
Substantia Nigra pars compacta has the overall effect of facilitating 
intended movement and inhibiting unintended movement. It does this 
by exciting the direct pathway and inhibiting the indirect pathway 
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through release of the neurotransmitter Dopamine. Striatal neurons of 
the direct pathway have D1 receptors which are excited by Dopamine, 
whereas Striatal neurons of the indirect pathway have D2 receptors 
which are inhibited by Dopamine. The Substantia Nigra pars compacta 
also sends excitatory input directly to the Cortex again using Dopamine. 
Parkinson's is a result of a disruption between the balance of the direct 
versus the indirect pathway. This balance is tipped more towards the 
indirect pathway resulting in less facilitation and more inhibition of 
movement. This disruption is caused by lesions of the Substantia Nigra 
pars compacta. This death of neurons in the pars compacta means that 
they can no longer release dopamine and excite the Striatal neurons in 
the direct pathway and inhibit the Striatal neurons in the indirect 
pathway. The pars compacta also can no longer excite the Cortex 
directly. 
Now due to the over-activity of the indirect pathway we see the signs of 
Parkinson's disease being exhibited. We understand why these are the 
symptoms because we know how the pathways within the Basal Ganglia 
function. All of the symptoms reflect the increase in inhibition of 
movement and the decrease in facilitation.  
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Figure 2. : Pathophysiology of Parkinson’s Disease. Simplified schematic diagram of 
the basal ganglia-thalamocortical circuitry under normal conditions (left) and rate 
changes in parkinsonism (right). Inhibited connections are shown as filled arrowds, 
excitatory connections as open arrows. The principal imput nuclei of the basal ganglia, 
the striatum and the STN (subthalamic nucleus), are connected to the output nuclei, 
Gpi and SNr. Basal ganglia output is directed at several thalamic nuclei (VA/VL and 
centromedian nucleus of thalamus shown as CM) and at brain stem nuclei 
(pedunculopontine nucleus shown as PPN and others). In parkinsonism, dopaminergic 
neurons in the SNc degenerate, which results via a cascade of change in the other 
basal ganglia nuclei, in increased basal ganglia output from Gpi and SNr. This, in turn, 
is thought to lead to inhibition of related thalamic and cortical neurons. 
 
2. Oxidative stress in Parkinson’s Disease 
Nigral dopaminergic neurons are particularly exposed to oxidative stress 
because the metabolism of dopamine gives rise to various molecules 
that can act as endogenous toxins if not handled properly (Figure 3). 
Dopamine can auto-oxidize at normal pH into toxic Dopamine-quinone 
species,  superoxide radicals and hydrogen peroxide. Alternatively, it 
can be enzymatically deaminated by monoamine oxidase (MAO) into the 
non-toxic metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) and 
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hydrogen peroxide (Maker HS et al., 1981). Superoxide is not a highly 
reactive molecule, but it can be converted to hydrogen peroxide by 
superoxide dismutase, or into labile peroxinitrite radicals in the 
presence of nitric oxide. Hydrogen peroxide is also innocuous, but can 
be broken down into cytotoxic hydroxyl radicals in a reaction that is 
catalysed by iron, the levels of which are higher in the substantia nigra 
than in other brain regions. Reactive oxygen species lead to functional 
alterations in proteins, DNA and lipids. Lipid damage, in turn, leads to 
loss of membrane integrity and increased permeability to ions such as 
calcium, which can promote excitotoxicity (Halliwell, B et al., 1992) 
(Figure 3). As cytoplasmic dopamine can quickly form reactive oxygen 
species, dopamine that has been synthesized or transported into the 
cell from the extracellular space has to be rendered harmless by rapid 
storage into small synaptic vesicles. By virtue of their low pH and the 
absence of MAO, these structures provide a stable environment for 
dopamine. Under normal conditions, efficient dopamine sequestration is 
probably the main pathway by which nigral cells protect themselves 
from the deleterious effects of dopamine oxidation. In Parkinson’s 
disease, however, nigral cells seem to be under a heightened state of 
oxidative stress, as indicated by elevations in by-products of lipid, 
protein and DNA oxidation, and by compensatory increases in 
antioxidant systems  (Mecocci P et al., 1993; Martilla RJ et al., 1988; 
Ben-Shachar D et al., 1991; Riederer et al.,1989; Jelliger K et al., 
1992; Dexter DT et al., 1989). 
Introduction 
 
 
- 19 - 
 
 
 
 
Figure 3. Cytoplasmic dopamine can form reactive oxygen species. An imbalance 
between the production and elimination of reactive oxygen species could contribute to 
the pathogenesis of Parkinson's disease and other neurodegenerative disorders. 
Metabolism of dopamine (DA) leads to the formation of several cytotoxic molecules, 
including superoxide anions (O2-), dopamine–quinone species (SQ) and hydroxyl 
radicals (OH). Dopamine breakdown can occur spontaneously in the presence of iron, 
or can be catalysed by monoamine oxidase (MAO) in a reaction that generates 
hydrogen peroxide (H2O2). Even though hydrogen peroxide is not damaging to cells, 
the formation of hydroxyl radicals by the Fenton reaction can lead to cytotoxicity. 
Normally, cells scavenge these deleterious molecules using several antioxidant 
systems. For instance, glutathione (GSH) peroxidase detoxifies hydrogen peroxide 
using reduced glutathione. Oxidized glutathione (GSSG) can be reduced by GSSG 
reductase and reused. GSH-S-transferase converts electrophilic centres of various 
potentially toxic compounds to thioether bonds. Superoxide dismutase converts 
superoxide to hydrogen peroxide. Catalase, in turn, converts hydrogen peroxide to 
molecular oxygen and water. In Parkinson's disease, however, an abnormal increase 
in the production of reactive oxygen species might tilt the balance between production 
and elimination, leading to enhanced oxidative stress. DOPAC, 3,4-
dihydroxyphenylacetic acid. 
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2.1 Role of Iron in Parkinson’s disease 
Iron may play a deleterious role in living cells by triggering of the 
oxidative stress via Fenton reaction (Halliwell B, 1989). Under 
physiological conditions this reaction takes place in cells without causing 
any damage because the amounts of the produced free radicals are not 
sufficient to start the stress. However an excess of divalent iron or a 
defect in annihilation of the radicals by scavengers may start the 
cascade of noxious events. The concentration of the total iron in 
parkinsonian and control substantia nigra was assessed by many 
authors with the use of various procedures (Gałazka-Friedman J et al., 
1997; Friedman A et al., 2007). Although according to many studies, 
most of iron is bound to ferritin, a controversy exists in the literature 
how much iron could be bound to neuromelanin. Some authors found 
iron bound to neuromelanin (Jellinger K et al., 1992), others did not 
(Hirsch EC et al., 1991). Another question is related to the placement of 
iron in neurons or in glia. In an interesting experiment using X-ray 
microanalysis an increase of iron concentration in individual neurons of 
SN was detected (Oakley AE et al. 2007). It may be concluded that the 
distribution of iron in SN is not homogenous. This also may affect the 
results obtained by various laboratories. The damage caused by iron is 
related to the oxidative stress triggered by Fenton reaction: 
Fe2+ + H2O2 ⇒ Fe3+ + OH• + OH−  
Iron is a strong prooxidant that catalyzes the production of hydroxyl 
radicals (Figure 4) leading cells to the death because of the severe 
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alterations of DNA, proteins, lipids and mithocondria. Although literature 
shows several contradiction regarding iron presence in the substantia 
nigra, the commonly reported increase of iron content in it suggests 
either an increase in iron penetration in the affected brain regions in 
patients with PD or a poor elimination of iron. 
 
 
Figure 4. Simplified scheme of iron-induced pathological cascade involved in 
neurodegeneration with brain iron accumulation associated with parkinsonian 
syndromes. Up to now, the hypothesis is that both, a genetic predisposition and endo- 
and/or exotoxins, may lead to enhanced iron levels that promote, primarily by means 
of the Fenton reaction, the formation of radicals that overwhelm the detoxification 
capacity of the cell, resulting in destruction of organelles and ultimately cell death. 
 
 
When the amount of iron exceeds the detoxification systems of the cell, 
increased levels of iron, especially Fe2+ enhance the Fenton reaction 
resulting in an amplification of oxidative stress (Riederer P et al., 1993). 
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This may induce a vicious circle as oxidative stress may increase the 
levels of free iron and so on.  
Oxidative stress is a common feature in many neurodegenerative 
disorders. The origin of the general oxidative stress in 
neurodegeneration is not fully understood and it is still unclear if the 
rise in iron concentration in the brain of patients with PD coud be a 
cause or an effect of PD.  
 
3. General Iron Metabolism 
Iron is an essential metal for the organism because of its unparalleled 
versatility as a biological catalyst. Consequently, iron is a crucial 
element required for growth. However, the very chemical properties of 
iron that allow this versatility also create a paradoxical situation, 
making acquisition by the organism very difficult. Indeed, at pH 7.4 and 
physiological oxygen tension, the relatively soluble iron (II) (Fe2+) is 
readily oxidized to iron (III) (Fe3+), which upon hydrolysis forms 
insoluble ferric hydroxides. As a result of this virtual insolubility and 
potential toxicity because of redox activity, iron must be constantly 
chaperoned. In fact, specialized molecules for the acquisition, transport, 
and storage of iron in a soluble, nontoxic form have evolved to meet the 
organism’s iron requirements. Because of its redox properties, iron can 
catalyze the production of reactive oxygen species (ROS) that can be 
highly toxic (Eaton JW et al., 2002). Therefore, under normal 
physiological conditions, iron is specifically transported in the blood by 
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diferric transferrin (Tf) (Klausner RD et al., 1983; Iacopetta BJ et al., 
1983). All tissues acquire iron by the binding of Tf to the transferrin 
receptor 1 (TfR1), with this complex then being internalized by 
receptor-mediated endocytosis (Klausner RD et al., 1983; Iacopetta BJ 
et al., 1983) (Figure 5A).  
 
 
Figure 5. Schematics of cellular iron uptake. (A) The process or iron uptake and 
utilization. (B) The “kiss and run” hypothesis. 
 
Within the endosome, the affinity of Tf for iron is decreased by the low 
pH generated through the activity of a proton pump (Ponka P,1997; 
Dunn LL et al., 2007). Importantly, the TfR1 facilitates liberation of iron 
from Tf in the pH range attained by the endosome (pH 5–5.5) (Bali PK 
et al., 1991). In vitro, iron release from Tf requires a “trap”, such as 
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pyrophosphate (Bali PK et al., 1991), but a physiological chelator 
serving this role has not been identified. In erythroid cells, once 
iron(III) (Fe3+) is released from Tf in the endosome, it is thought to be 
reduced to iron(II) (Fe2+) by a ferrireductase in the endosomal 
membrane known as the six-transmembrane epithelial antigen of the 
prostate 3 (STEAP3) (Ohgami RS et al., 2005; Sendamarai AK et al., 
2008)  (Figure 5A). After this step, Fe2+ is then transported across the 
endosomal membrane by the divalent metal transporter-1 (DMT1) 
(Fleming MD et al., 1998) and forms, as generally believed, the 
cytosolic low Mr (Relative Molecular Mass) labile or chelatable iron pool 
(Jacobs A, 1977). This pool of iron is thought to supply the metal for 
storage in the cytosolic protein ferritin and for metabolic needs, 
including iron uptake by the mitochondrion for heme and Iron-Sulfur 
clusters (ISCs) synthesis. Iron can also be released from the cell by the 
transporter ferroportin1 (Ganz T, 2007) (Figure 5A).  
Ferroportin1 expression can be regulated by the hormone of iron 
metabolism, hepcidin. Hepcidin is a key regulator of systemic iron 
metabolism (Ganz T, 2007) and is transported in the blood bound to 
α2–macroglobulin (alpha 2-macroglubulin) (Ganz T, 2007).  Hepcidin 
secretion by the liver is stimulated by high iron levels and also 
inflammatory cytokines, such as interleukin-6 (Ganz T et al., 2009).  
The chelatable iron pool is thought to control the activity of IRPs-1 and 
-2 (Figure 6). The IRPs are RNA-binding proteins that bind to IREs in 
the 3′- and 5′-untranslated regions in mRNAs of molecules playing 
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crucial roles in the uptake, utilization, export, and storage of iron (e.g., 
TfR1, ferritin, etc.) (Hentze MW et al., 2004). IRP-1 performs two 
functions: (1) regulating iron homeostasis via binding IREs and (2) 
having cytosolic aconitase activity when containing an [4Fe-4S] cluster 
(Hentze MW et al., 1996). IRP-2 is thought to be the principal RNA-
binding protein in vivo and is regulated by iron-dependent proteasomal 
degradation (Cairo G et al., 2007; Meyron-Holtz EG et al., 2004; 
Meyron-Holtz EG et al., 2004). Once iron is transported out of the 
endosome via DMT1, it enters the chelatable (and stored in ferritins) or 
labile iron pool (Figure 5A) or, alternatively it is deliverd to mithocondria 
in a still unclear way. A direct transfer of iron from Tf to the 
mitochondrion was proposed to occur (Isobe K et al., 1981; Ponka P et 
al., 1976). This idea has developed in more recent years and has led to 
the “kiss and run” hypothesis (Ponka P, 1997) (Figure  5B). This model 
suggests that a direct transfer of iron from the Tf-containing endosome 
to the mitochondrion occurs, by-passing the cytosol (Ponka P, 1997; 
Zhang AS et al., 2005). 
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Figure 6. Iron metabolism regulation by IRPs. Iron regulatory proteins control cellular 
iron homeostasis. A) Transcripts containing iron-regulatory elements (IREs) in either 
their 5′ or 3′ Untranslated Regions (UTR) are bound by iron regulatory proteins (IRPs) 
when iron levels are perceived to be low. IRP binding to 5′ IREs provides steric 
hindrance to ribosomal machinery, leading to decreased translation of the transcript. 
IRP binding to 3′ IREs blocks the action of exonucleases, thereby protecting the 
transcripts from degradation and increasing translation. Transcripts that contain IREs 
in either their 5′ or 3′ UTRs are listed. Note: There are four isoforms of DMT1 mRNA, 
only some of which contain 3′ UTR IREs. Abbreviations: ferritin-H/-L, Ft-H/-L; 
mitochondrial aconitase, mt-aconitase; aminolevulinic acid synthase 2, ALAS2; 
hypoxia inducible factor 2α, HIF2 α; amyloid β precursor protein, AβPP; transferrin 
receptor 1, TfR1; divalent metal transporter with IRE, DMT1+IRE; cell division cycle 
14 homolog A, CDC14A. B) When it contains a functional ISC, IRP1 (red) functions as 
a cytosolic aconitase (converting citrate to isocitrate); in the absence of a functional 
ISC it is converted to an IRE-binding protein. The status of the ISC can change in 
response to decreased ISC production or increased ISC disruption by reactive oxygen 
species (ROS). IRP2 (yellow) is a constitutive IRE-binding protein that is regulated by 
proteasomal degradation. When cellular iron and oxygen levels are adequate, FBXL5 
(green) can complex with SKP1 (blue) and CUL1 (purple) to form a functional E3 
ubiquitin ligase that tags IRP2 for degradation (light yellow). 
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3.1 Iron Metabolism and its “essential proteins” 
Although it is strongly incorrect use the term “essencial” referred to 
only two proteins involed in iron metabolism, in this context it is 
necessary spent few words about the previously described Divalent 
Metal Iron Transporter DMT1 and the Transferrin Receptors: 
 
- DMT1 
The divalent metal transporter 1 (DMT1), also known as natural 
resistance-associated macrophage protein 2 (NRAMP 2), and divalent 
cation transporter 1 (DCT1), is a protein that in humans is encoded by 
the SLC11A2 (solute carrier family 11, member 2) gene (Vidal S et al., 
1995). DMT1 represents a large family of orthologous metal ion 
transporter proteins that are highly conserved from bacteria to humans 
(Au C et al., ). As it's name suggests, DMT1 binds a variety of divalent 
metals including cadmium (Cd2+) and copper (Cu2+), however it is best 
known for it's role in transporting ferrous iron (Fe2+); DMT1 expression 
is regulated by body iron stores to maintain iron homeostasis. DMT1 is 
also primary in the absorption and transport of manganese (Mn2+). 
DMT1 expression in the brain may increase with age (Ke Y et al., 2005), 
increasing susceptibility to metal induced pathologies. DMT1 expression 
is found to be increased in the substantia nigra of Parkinson's patients 
and in the ventral mesencephalon of animal models intoxicated with 1-
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methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) - a neurotoxin 
widely used experimentally to produce Parkinsonian symptoms.  
Two mRNA isoforms differ in the 3' UTR: DMT1 +IRE has an IRE (Iron 
Responsive Element) but DMT1-IRE lacks this feature. The +/-IRE 
proteins differ in the distal 18 or 25 amino acid residues after shared 
identity for the proximal 543 residues. A major function is serving as 
the apical iron transporter in the lumen of the gut. The +IRE isoform 
appears to have that role. Another role is endosomal exit of iron. Some 
evidence indicts the -IRE isoform for this function. As a consequence, 
while the +IRE isoform can be regulated in its expression by the IRPs 
proteins, this can not happens for the –IRE isoform.   
- TfRs 
Transferrin receptor (TfR) is a carrier protein for transferrin. It is 
needed for the import of iron into the cell. It imports iron by 
internalizing the transferrin-iron complex through receptor-mediated 
endocytosis. There are 2 different genes encoding for two different 
forms of Transferrin Receptors: (1) TfR1 (also called TfRC) is expressed 
quite ubiquitously and contains the IRE sequence in the 3’UTR of the 
mRNA encoding for it, (2) TfR2 is expressed less ubiquitously respect to 
TfR1. It is the principal Transferrin Receptor expressed, for exemple in 
the liver  but a recent study (Mastroberardino PG et al., 2009) shows its 
strong expression in dopaminergic neurons in Parkinson’s disease. Even 
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in this case, while TfR1 contains an IRE sequence in the 3’UTR of the 
mRNA encoding for it, TfR2 can not be regulated by IRPs. 
The previously described observations arise an important question: is it 
supposable that proteins such as DMT1 –IRE and TfR2, so 
strongly involved in iron uptaking and homeostasis are 
regulated by a mechanism microRNA-mediated?  
Few years ago, our group demonstrated that that in erythroid cells, 
DMT1-IRE expression is under the regulation of miR-Let-7d. DMT1-IRE 
and miR-Let-7d are inversely correlated with CD34(+) cells, K562 and 
HEL cells during erythroid differentiation. Moreover, overexpression of 
miR-Let-7d decreases the expression of DMT1-IRE at the mRNA and 
protein levels in K562 and HEL cells. MiR-Let-7d impairs erythroid 
differentiation of K562 cells by accumulation of iron in the endosomes 
(Andolfo I et al., 2010). 
To date, no information regarding a putative microRNA-mediated 
mechanism of regulation of TfR2 is available in literature.  
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4. MicroRNAs (miRNAs) in brief 
In recent years, our understanding of miRNAs has grown from the 
discovery of a single genetic oddity in worms to the recognition of an 
entirely new class of regulatory molecule with thousands of members 
(Griffiths-Jones S et al.,2008). The significance of miRNAs in normal 
development and cellular function is underscored by mounting evidence 
that misregulation of specific miRNA pathways is associated with 
complicated health afflictions, including cancer, heart disease and 
neurological disorders (Hebert  SS et al., 2009; Latronico MV et al., 
2009; Negrini M et al., 2009). miRNAs are intertwined in complex 
regulatory pathways in plants as well5 and represent one of the most 
plentiful classes of gene regulators in multicellular organisms. 
Production of the functional, ~22-nt mature miRNA involves multiple 
processing steps (Chen X, 2009; Davis BN et al., 2009; Winter J et al., 
2009)  (Figure 7). The general miRNA biogenesis pathway begins with 
synthesis of a primary transcript by RNA polymerase II (Pol II). Housed 
within the primary transcript is the hairpin precursor, which contains the 
sequence destined to be the mature miRNA in one arm of the stem. In 
animals, the Microprocessor complex, minimally composed of the 
Drosha RNase (RNase) and its RNA binding partner Pasha (also called 
DGCR8), releases the miRNA precursor from the primary transcript. 
Exportin-5 delivers the precursor to the cytoplasm for final processing 
by the Dicer RNase and its double-stranded RNA binding cofactor TRBP 
(also called loquacious, Loqs). After loading onto Argonaute, one strand 
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of the resulting partial duplex, designated the guide, is preferentially 
retained.  
 
 
Figure 7. A general model of miRNA biogenesis and function. After synthesis by RNA 
polymerase II, miRNA primary transcripts are recognized by Pasha/DGCR8 and 
Drosha, which excises the hairpin precursor. Exportin 5 delivers the miRNA precursor 
to Dicer and its RNA binding partner, TRBP/Loqs, for final processing to the mature 
22-nt miRNAs. One strand is selected for stable association with Argonaute, where it 
serves as a guide to target and regulate specific mRNAs. 
 
This multistep pathway is shared in plants with a few exceptions: the 
Dicer-like (DCL) proteins catalyze both the primary and precursor 
processing steps in the nucleus, where the mature miRNA forms a 
complex with Argonaute and is transported to the cytoplasm. miRNAs 
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serve as guides to direct the Argonaute complex to target mRNAs 
through complementary base-pairing (Chen X, 2009; Chekulaeva M et 
al., 2009). Typically, target recognition results in destabilization or 
translational repression, either of which ultimately silences gene 
expression. Accumulation of a specific miRNA is dependent on the rates 
of transcription, processing and decay. Similar to the expression of 
many protein-coding genes, expression of miRNA primary transcripts is 
subject to regulation by specific transcription factors and chromatin 
marks (Chen X, 2009; Davis BN et al., 2009; Winter J et al., 2009). 
Control of each processing step has also emerged as a key determinant 
of functional miRNA expression. The first global analysis of primary and 
mature miRNA levels revealed that extensive post-transcriptional 
regulation is involved in cellular miRNA homeostasis (Thomson JM et 
al., 2006). Several examples of proteins and mechanisms that govern 
processing of specific miRNAs are detailed in recent reviews (Davis BN 
et al., 2009; Winter J et al., 2009). 
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4.1. MicroRNAs and Neurodegenerative Diseases 
“Neurodegeneration” is a term that has been used to refer to differing 
topics. Abundant nerve cell death occurs in the course of normal brain 
development, and many pediatric neurological diseases are 
characterized by pathological degeneration of neurons and/or muscles. 
Phenomena involving nerve cell death also occur in animal models and 
cells in culture. In the course of NDs, neurons lose their connections 
and die prematurely. There are six general ideas that are relevant at 
least circumstantially to how microRNA (miRNA) biochemistry may 
interact with the pathogenesis of Neurodegenerative Diseases (NDs): 
1) Most NDs are not inherited in patterns that reflect simple 
Mendelian genetics. Most prevalent subtypes of NDs, such asAD and 
PD, are inherited in a manner termed “sporadic” (as opposed to 
“familial”), influenced by alleles with limited genetic penetrance, or are 
caused by genetic and/or environmental influences as yet 
uncharacterized. These facts may shift the focus of ND genetic studies  
away from “traditional” genes which constitute only ~1%–2% of human 
DNA, and towards the other ~50% of transcribed DNA about which we 
are mostly ignorant. 
2) Brains of human ND patients show evidence of chronic stress. 
ND brains show evidence of considerable cellular stress. Although this 
may be expected in disease processes that last for long periods and 
involve abundant cell death, this response may prove contributory 
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because the stress response itself could play a role in the “cascade” 
effect (see below) that result ultimately in neurological deficits. 
3) NDs may be exacerbated in the clinicobiological sense by the 
aberrant stimuli of developmental pathways. Some biochemical 
pathways that are up-regulated during normal brain development, but 
down-regulated in normal adulthood, are then aberrantly up-regulated 
again in the course of NDs. These include pathways involved in cell–cell 
signaling, cell division, neuroplasticity and apoptosis (Arendt T, 2005; 
Bothwell M et al., 2000; Nguyen MD et al., 2002). In the case of the 
microtubule-associated protein tau (MAPT), there is an mRNA splicing 
variant that is more highly represented both in early development and 
in some neurodegenerative diseases (Kar A et al., 2005; Nelson PT et 
al., 2007). Furthermore, the developmentally up-regulated 
phosphorylation of MAPT is also up-regulated in AD neurofibrillary 
pathology (Goedert M, 2004; Stoothoff WH et al., 2005). These are only 
a few examples of how the up-regulation of developmental pathways in 
the adult milieu may contribute to the pathological progression of some 
NDs. 
4) RNA is pathologically altered in NDs RNA biochemists are well 
aware that RNA is labile in even tightly controlled circumstances. In the 
course of some NDs, brain RNAs becomes pathologically altered 
(Markesbery WR et al., 2007; Nelson PT et al., 2007; Smith MA et al., 
2000). These changes include aberrant RNA oxidation, RNA 
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degradation, altered RNA splicing and ribosomal changes which cause 
mRNA translational frame-shifting abnormalities. 
5) Human NDs are chronic conditions that last for decades 
rather than just for several years. Recent studies have established 
the surprising chronicity of the processes underlying NDs. UsingAD as 
an example, the time from patients’ clinical diagnosis to death is 
typically ~8 years (Williams MM et al., 2006). However, the underlying 
pathological processes of AD occur over many decades. Persons at risk 
for developingAD in their seventh or eighth decade already show brain 
metabolic abnormalities by PET scan even in their third decade of life 
(103 Reiman EM et al., 2004; Scarmeas N et al., 2005). These are 
important data because they show that ND pathology involves a 
longevolving shift in cellular equilibrium, which could be “tipped” even 
by subtle genetic and/or environmental influences.  
6) Pathogenetic mechanisms of ND involve multiple distinct 
Steps. Most NDs are probably not just a “one-hit” phenomenon, but 
rather they probably involve a sequential progression of pathological 
processes that result collectively in neuronal death and/or compromised 
connectivity. 
These six features of NDs dovetail on some of the known characteristics 
of miRNA biochemistry in the brain. As described below, miRNAs derive 
from “non-traditional genes”; are related to pathways of cellular stress 
and neurodevelopment; may be altered by the changes seen in ND 
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brains such as oxidation; and may ultimately contribute to step(s) that 
culminate in chronic brain diseases. 
One unexpected characteristic of some human miRNAs is their very high 
RNA copy number per cell. Particular miRNAs can be represented by 
1000 – 30000 copies per cell or more (Allawi HT et al., 2004; Lim LP et 
al., 2003). By comparison, the large majority of mRNAs typically 
number less than 100 copies per cell (Carter MG et al., 2005; Sheng HZ  
et al., 1994). If miRNAs participate in gene expression regulation and 
are represented in high numbers per cell, how extensive is the cellular 
impact of miRNAs? Numerous studies have now established that 
miRNAs can have a profound cellular impact by dint of sheer 
biochemical promiscuity: each miRNA can regulate hundreds, thousands 
or more mRNA targets. This was first indicated by predictive , which 
showed that evolutionarily conserved “miRNA recognition elements” are 
present in the 3′ untranslated region (3′UTR) of very many mRNAs per 
miRNA (Bentwich I, 2005; John B et al., 2004; Kiriakidou M et al., 
2004; Lewis BP et al., 2003; Lewis BP et al., 2005; Maziere P et al., 
2007). Hence, these small non-coding RNAs, which are present in very 
high gene copy numbers and which work through a powerful 
translational regulation paradigm, can modify an exceptionally large 
number of genes. 
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4.2. MicroRNAs in cellular stress 
Cellular stress is a conspicuous feature of ND brains. A detailed catalog 
of the many roles now thought to be played by miRNAs in stress is 
beyond the scope of this review. However, miRNAs’ expressions have 
been shown to change dramatically in response to cold and heat stress, 
hypoxia, oxidative stressors, arsenic, irradiation, nutrient deprivation 
and other stresses (Ambros V, 2003; Chiou TJ, 2007; Dresios J et al., 
2005; Ishii H et al., 2006; Lukiw WJ et al., 2007; Marsit CJ et al., 2006; 
Rocha S, 2007; van Rooij E et al., 2006; Sunkar R et al., 2007). 
Typically, in stress conditions, a subset of miRNAs are increased, and a 
subset are decreased. The subset of miRNAs that are altered in one 
stress condition and in one cell type are not necessarily related to the 
miRNAs which change expression upon a different stressful stimulus. 
The biochemical effects of miRNAs during cellular stress can change 
dramatically. For example, stress may alter a miRNA : mRNA interaction 
to produce translational up-regulation of target mRNAs (Bhattacharyya 
SN et al., 2006; Huang J et al., 2007), which is the opposite of 
“canonical” miRNA activity. This has prompted speculation that miRNAs 
may constitute a “safeguard against turmoil”, by altering globally the 
parameters of translational machinery in the cells during stress (Leung 
AK et al.,2007). In summary, during any conditions that are 
attended by cellular stress, such as NDs, it can be expected that 
miRNA expression patterns will change, which would be 
expected in turn to alter the translation of a large number of 
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different cellular mRNAs. Most of the details of how miRNAs 
participate in neurodegeneration have yet to be worked out. Hence, at 
this point, one may consider that the current research corpus is mostly 
a platform for future gains. Figure 8 shows some of the possibilities 
related to the interactions between miRNAs and NDs. 
 
Figure 8. A schematic diagram about some roles miRNAs may play in NDs. The brains 
of persons at risk for NDs are subjected to chronic stimuli that can perturb specific 
and/or global miRNA expression. Either the aberrant stimulation or inhibition of miRNA 
expression may be associated with pathways involved in NDs or neuroprotection. 
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5. Aim of the study 
In human brain the gratest amount of iron is localized in basal ganglia 
(Riederer et al.,1989), moreover, in old age a strong increase of its 
concentration is found in both humans and animal models (Zecca et 
al., 2001; Hahn et al.,2009). The main feature of many 
neurodegenerative diseases is the difficoulty in the regulation and 
keeping of iron homeostasis. In Parkinson’s Disease high concentration 
of iron  have been observed in substantia nigra, a sub-region inside 
basal ganlia, subject to dopaminergic neurodegeneration which during 
the outcome of the disease is associated with motor disfunction. This 
increase can lead to unbalance and consequently iron overload 
determining the inability of neurons and other brain cells inside basal 
ganglia to try to avoid this  toxic overload. Iron role in the 
phathogenesis of PD has been widely studied in the last two decades. 
Many scientific evidences confirm that among the causes iron can 
interact and interfere with normal dopaminergic functions or other 
features associated to PD (Pezzella et al., 1997; Hashimoto et al., 
1999). Alterations of one of the many components involved in the 
delicate balance between iron cellular transport and iron absorption and 
storage can cause a loss of its homeostasis and contribute to 
dopaminergic neurodegeneration. On these basis, great part of scientific 
literature questioned on which could be the mechanism that regulates 
genes involved in  iron metabolism dysregulation. As explained before, 
TfR2 is mainly expressed in dopaminergic neurons of substantia nigra in 
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PD (Mastroberardino et al., 2009), moreover its post-transcriptional 
expression is not regulated by IRPs as it does not contain an IRE at the 
3’UTR of the mRNA encoding for it. Being TfR2 a receptor expressed on 
cell membrane, involved in iron uptake, and being Parkinson’s Disease 
characterized by iron overload, this study is oriented to investigate 
about the possible regulation of TfR2 expression by microRNAs. This 
hypothesis is supported by the evidence that other genes involved in 
iron metabolism are actually regulated by microRNAs. In fact, from a 
previously published study, developed in our laboratory, it has been 
demonstrated that Let-7d microRNA is able to regulate the expression 
of DMT1 –IRE transporter during erythroid cell differentiation (Andolfo 
et al., 2010). Literature is very poor of informations about the specific 
DMT1 –IRE and +IRE isoforms in Parkinson’s Disease, these few 
informations appear very contrasting: while a recent study shows the 
down-regulation of DMT1 –IRE and the up-regulation of DMT1 +IRE 
(Salaza J et al., 2008), a genomic study failed to show DMT1 (in 
general, so not referred to a specific isoform) up-regulation in an M9D 
dopaminergic cell line treated with MPP+ (Wang J et al., 2007) and 
another recent study using MES23.5 dopaminergic cells shows that 
MPP+ treatment is sufficient to increase DMT1 -IRE expression 
increasing iron uptake because of a major iron infflux (Zhang S et al., 
2009).  
Different questions arised on the basis of these observations and are 
the object of this study: 
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1) I enquired if TfR2, so largely involved in iron uptake al neuronal 
level, coud be regulated by microRNAs; 
2) I enquired about the up- or the down-regulation of DMT1 –IRE 
isoform in my cellular model of Parkinson’s Disease; 
3) I enquired about a possible microRNA Let-7d regulated expression of 
DMT1 –IRE isoform in the in vitro model used for this study. 
For this, the final task was that of identify putative microRNAs which 
could be involed in the regulation of the expression of both DMT1 –IRE 
and TfR2 in an in vitro model of Parkinson’s Disease through the 
following steps: 
- Bioinformatics selection of microRNAs and following evaluation of their 
basal expression in the chosen cellular model; 
- Evaluation of the effectiveness of binding between selected microRNAs 
and the 3’UTR from studied genes; 
-MicroRNAs overexpression and evaluation of the effects on the 
expressions of the studied genes/proteins in the “in vitro” Parkinson’s 
Diesease model. 
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5.1 Cellular Model: SH-SY5Y cells treated with MPP+ 
SH-SY5Y 
SH-SY5Y cells were chosen as cell line to reproduce an “in vitro” PD 
model, as it shows specific dopaminergic features like neurons in 
substantia nigra. Human Neuroblastoma Cells SH-SY5Y are a 
neuroblastic subclone extensively characterized by SK-N-SH 
(Nakagawa-Yagi et al., 1991;  Seidenfaden et al., 2006), obtained in 
1970 from methastatic neuroblastic tissues of a four years old female 
child (Biedler et al., 1973). Neuroblastoma is a tumor with its onset in 
pediatric age which originates from immature neuroblasts during the 
periferic nervous system develpement (Olsson et al., 2000). SH-SY5Y 
cell line is a cellular population with a simil-neuroblasts morphology, 
with the cell body similar to a drop (Jalava et al., 1990) and the cells 
also show short axons, growing in large part as a single layer in cell 
colture dishes (Biedler et al., 1973), while a small amount of cells, is 
suspended in the medium and represents cells in mithosis. These cells 
are a well characterized model for in vitro differentiation studies as a 
simil-neuronal phenotype that can be induced by the use of various 
exogen differentiating agents such as retinoic acid, nerve growth factor 
(NGF) and others (Seidenfaden et al., 2006; Peterfreund et al., 1997; 
Ammer e Schulz, 1994). Differentiation of these cells is associated with 
the extension of long axons and can be quantified through 
morphological analysis of the axon genesis (Jalava et al., 1990, 
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Seidenfaden et al., 2006). SH-SY5Y cell line is widely used as a model 
for the study of neuronal cell death caused by oxidative stress, 
associated with various chronic neurodegenerative diseases as 
Parkinson’s Disease, Alzheimer’s Disease and Huntington Disease 
(Ruffels et al., 2004). Scientific evidences show that the treatment of 
these cells with retinoic acid is not necessary when used as in vitro 
model of Parkinson’s Disease. Therefore undifferentiated SH-SY5Y is 
more appropriate in experimental Parkinson’s Disease research (Cheung 
YT et al. 2009). 
5.2. MPP+ 
MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, also known as 
“synthetic heroin”) is a secondary product which is formed during the 
meperidine synthesis. It can lead to a reversible form of Parkinson’s 
Disease which can be blocked by interrupting the consumption of this 
substance. It is also used as a fast-acting opioid analgesic drug. The 
MPTP alone does not have oppioid effect, but can be accidentally 
produced during illegal creation of MPPP (1-Methyl-4-phenyl-4-
propionoxypiperidine). MPTP has side effects as its intake causes 
Parkinson’s symptoms, since some MPPP users develops these 
symptoms. MPTP crosses very well the blood-brain barrier, enters glial 
cells where monoamino oxidase B enzymes (MAO-B) oxidate it in MPP+ 
(1-methyl-4-phenylpyridine). MPP+ enters dopaminergic cells localized 
in the substantia nigra, exploiting the dopamine carrier, causing 
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neuronal death as it inhibits mithocondrial respiration; as a 
consequence, oxidative stress and damage is generated along with 
more damage. MPTP neurotoxicity was discovered in 1976 after Barry 
Kidston, a 23 years old chemistry student in Maryland, synthetized and 
injected MPPP contaminated with MPTP; after three days he showed 
Parkinson’s Disease symptoms. National Institute of Mental Health 
found traces of MPTP in his laboratory and found by accident its effects 
while experimenting on mice. In 1982 in seven people from Santa Clara 
County, California, Parkinson’s Diseases was diagnosed after using 
MPPP contaminated with MPTP. Later, the neurologist J. William 
Langston, in collaboration with NIH, proved the MPTP effects, testing it 
on primates. 
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Materials and Methods 
 
1. Bioinformatics Selection of microRNAs 
PITA tool  
(http://genie.weizmann.ac.il/pubs/mir07/mir07_data.html) 
is an algorithm that is used to predict miRNA targets. It is based on a 
parameter-free model for microRNA-target interactions that computes 
the differences between the free energy gainedfrom the formation of 
the microRNA-target duplex and the energetic cost of unpairing the 
target to make it accessible to the microRNA. The site accessibility is as 
important as the sequence match in the seed for determining the 
efficacy of microRNA-mediated translational repression, and the 
effective microRNA binding also requires the local region flanking the 
target to be unpaired. The energy-based scores for microRNA-target 
interactions, ΔΔG, predicted by the PITA tool are equal to the difference 
between the free energy gained by the binding of the microRNA to the 
target, ΔGduplex, and the free energy lost by unpairing the target-site 
nucleotides, ΔGopen. 
TargetScan 
(http://www.targetscan.org/) 
TargetScan predicts biological targets of miRNAs by searching for the 
presence of conserved 8mer and 7mer sites that match the seed region 
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of each miRNA. As an option, nonconserved sites are also predicted. 
Also identified are sites with mismatches in the seed region that are 
compensated by conserved 3' pairing. In mammals, predictions are 
ranked based on the predicted efficacy of targeting as calculated using 
the context + scores of the sites. As an option, predictions are also 
ranked by their probability of conserved targeting. 
MicroCosm 
(http://www.ebi.ac.uk/enright-
srv/microcosm/htdocs/targets/v5/) 
MicroCosm Targets (formerly miRBase Targets) is a web resource 
developed by the Enright Lab at the EMBL-EBI containing 
computationally predicted targets for microRNAs across many species. 
The miRNA sequences are obtained from the miRBase Sequence 
database and most genomic sequence from EnsEMBL.  
 
The 3’UTR of the studied genes were submitted to every previously 
described bioinformatics tools in order to obtain a list of microRNAs 
potentially binding it, helped by the score associated to microRNAs. The 
more the score is negative, the more the binding probability is high. 
Moreover, outputs from all the used tools were compared in order to 
select the microRNAs with the higher probability of binding. 
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2. Standard Cell Coltures 
The K562 human myeloid leukemia cell line, the HEK293 human 
embryonic kidney cell line and the SH-SY5Y neuuroblastoma cell line 
were obtained from American Type Culture Collection (ATCC, Manassas, 
VA, USA).  
K562 cells were maintained at 37°C with 5% CO2 in Iscove’s medium 
(Sigma Aldrich, Milan, Italy), supplemented with 10% fetal bovine 
serum (FBS) (Celbio Pero, Milan, Italy), 10 U/mL penicillin and 0.1 
mg/mL streptomycin (Pen/Step) (Celbio Pero).  Hek 293 cells were 
maintained at 37°C with 5% CO2 in Dulbecco's Modified Eagle'sMedium 
(DMEM) (Sigma Aldrich, Milan, Italy) supplemented with 10% fetal 
bovine serum (FBS) (Sigma Aldrich, Milan, Italy), 10 U/mL penicillin and 
0.1 mg/mL streptomycin (Pen/Step) (Celbio Pero). SH-SY5Y cells lines 
were grown in Dulbecco’s Modified Eagle’s medium (DMEM) (Sigma 
Aldrich, Milan, Italy) supplemented with 10% fetal bovine serum (FBS) 
(Sigma Aldrich, Milan, Italy), 10 U/mL penicillin and 0.1 mg/mL 
streptomycin (Pen/Step) (Celbio Pero). 
 
3. MTS assay 
SH-SY5Y cells were treated with two different concentration of MPP+, 
respectively 0.5 mM and 1 mM. Cell viability after 24 hours, 48 hours 
and 72 hours was evaluated by an MTS assay performed by using 
CellTiter 96® AQueous One Solution Cell Proliferation Assay System 
(Promega, Madison, WI, USA). It is a colorimetric method to determine 
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the number of viable cells in proliferation or cytotoxicity assays and 
contains a tetrazolium compound [3-(4,5-dimethyl-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] that is 
reduced in presence of NADH and NADPH produced by active cells 
methabolism. 
 
4. RNA extraction from SH-SY5Y cells 
Cells were detached from colture dished using 1 mL of  trypsin 0,05% and 
EDTA 0,02% solution. Subsequently cells were washed twice in a 
phosphate-buffered saline (PBS) (Sigma Aldrich, Milan, Italy) and lysate 
by 1 mL of Trizol Reagent (Invitrogen, La Jolla,CA, USA). Samples were 
then incubated for 5 minutes at room temperature. A volume of 200 μL 
of chloroform was added and the solution was mixed for 15 seconds, incubated for 
2-3 minutes at room temperature and then centrifugated for 15 minutes at 
12000xg at 4°C to obatain two phases. RNA contained in the superior white phase 
was precipitated by adding 500 μL of isopropyl alcohol and the solution was 
incubated for 10 minutes on ice. A subsequent centrifugation step (12000xg, 15 
minutes, 4°C) allowed the precipitation of the RNA pellet. This pellet was washed  
in ethanol 75% diluited in a H2O-diethylpyrocarbonate (DEPC) solution. 
Finally, RNA was resuspended in a H2O-diethylpyrocarbonate (DEPC) 
solution. 
 
5. cDNA synthesis 
2 μg di RNA were retro-trancribed using iScript™ cDNA Synthesis Kits 
(BioRad, Milan,Italy) in order to  synthesize single strand cDNAs. In a 
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finale volume of 20 μL were added 4μl of 5x iScript Reaction Mix, 1μl of 
iScript Reverse Transcriptase and Nuclease-free water till to reach the 
20 μL. The complete reaction mix was incubated  for 5 minutes at 25ºC 
followed by 30 minutes at 42ºC and a final step for 5 minutes at 85ºC. 
 
6. TaqMan miRNAs assay 
Reverse transcriptase reactions contained 40 ng RNA sample, 50 nM 
stem–loop reverse transcriptase primer, 1x reverse transcriptase buffer 
(P/N:4319981, Applied Biosystems, Branchberg, NJ, USA), 0.25 mM 
each of the dNTPs, 3.33 U/mL MultiScribe reverse transcriptase (P/N: 
4319983, Applied Biosystems) and 0.25 U/mL RNase inhibitor (P/N: 
N8080119; Applied Biosystems). The 15-μL reactions were incubated in 
an Applied Biosystems 9700 Thermocycler for 30 min at 16°C, 30 min 
at 42°C, and 5 min at 85°C, and then held at 4°C. Real-time (RT)-PCR 
was performed using a standard TaqMan PCR kit protocol on an Applied 
Biosystems 7900HT Sequence Detection System. The 20-μL PCRs 
included 2 μL reverse transcriptase product, 10 μL TaqMan Universal 
PCR Master Mix (Applied Biosystems), 0.2 mM TaqMan probe (for 
microRNA Let-7d, microRNA 221, microRNA-RNU6 and all the other 
microRNAs assayed). The reactions were incubated in a 96-well plate at 
95°C for 10 min, followed by 40 cycles of 95°C for 15 sec, and 60°C for 
1 min. 
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7. Vector cloning (pre-microRNAs) 
Pre-miR-Let-7d, pre-miR-221 and pre-miR-222 were cloned into a 
pcDNA3.1 vector (Promega, Madison, WI, USA) using the EcoRI–XhoI 
restriction sites.  
Inserts preparations 
All the cloned pre-miR were amplified from genomic DNA using the 
following primers: 
Pre Let7d Clo F: CGGGAATTCCCTAGGAAGAGGTAGTA 
Pre Let7d Clo R: CGGCTCGAGCCTAAGAAAGGCAGCAG 
Pre 221 Clo F: AAACCTCGAGGAGAACATGTTTCCAGGTAG 
Pre 221 Clo R: AAAAGAATTCTGAACATCCAGGTCTGGGGC 
Pre 222 Clo F: AAACCTCGAGAGCTAGAAGATGCCATCAGA 
Pre 222 Clo R: AAACGAATTCGCTGCTGGAAGGTGTAGGTA 
The complete reaction mix for every amplified pre-microRNA contained 
200 ng of genomic DNA, 1 μl of forward primer (10μM), 1 μl of reverse 
primer (10μM), 25 μl of Master Mix (Promega, Madison, WI, USA) and 
water to reach a final volume of 50 μl. Reactions were incubated in 
Veriti Thermal Cycler (Applied Biosystems, Branchberg, NJ, USA) 
according to the following program: an initial step at 94°C  for 5 
minutes followed by 35 cycles at 94°C for 30 seconds, 58°C for 30 
seconds, 72°C for 30 seconds and a final elongation step at 72°C for 7 
minuts. The amplification products were visualized on 1.5% agarose gel 
(BioRad, Milan, Italy) and subsequently digested with restriction 
enzymes according to the following protocol: 3 μl Buffer 2 (10X) (New 
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England Biolabs), 0.8 μl EcoRI (20.000 U/ml) (New England Biolabs), 0.8 
μl XhoI (20.000 U/ml) (New England Biolabs) and water to reach the 
final volume of 30 μl. The digestion was carried on for 4 hour at 37°C 
and then enzymes were inactivated at 65°C for  20 minutes. 
Vector Preparation 
2000 ng of pcDNA3.1 vector were digested using 3 μl Buffer 2 (10X) 
(New England Biolabs), 0.8 μl EcoRI (20.000 U/ml) (New England 
Biolabs), 0.8 μl XhoI (20.000 U/ml) (New England Biolabs) and water to 
reach the final volume of 30 μl. The digestion was carried on for 4 hour 
at 37°C and then enzymes were inactivated at 65°C for  20 minutes. 
Subsequently, 1000 ng of digested vector were dephosporilated at the 
5’ end using 3μl of NEB buffer Antarctic phosphatase (10X), 1μl of 
Antarctic phosphatase (New England Biolabs) and water to reach the 
final volume of 30 μl. The reaction was incubated at 37°C for 2 hours 
and then the enzyme was inactivated for 20 minutes at 65°C. The 
digested an dephosporilated vector, was finally purified from agarose 
gel (1%) (BioRad, Milan,Italy) using QuiaQuik gel extraction Kit 
(Quiagen).  
 
8. Vector cloning (3’UTRs) 
The full-length 3’UTR of the mRNA encoding for both DMT1 –IRE and 
TfR2 were cloned into the pRL-TK vector (Promega, Madison, WI, USA) 
downstream of the coding region of Renilla Luciferase in the XbaI site. 
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Inserts preparation: 
The 3’-UTR of DMT1-IRE and TfR2  were amplified from genomic DNA 
using the following primers, containing at the 5’ end the restriction site:  
DMT1 –IRE Clo F: CCCTCTAGACAGCTCATTCTGGCATTCAA 
DMT1 –IRE Clo R: CCCTCTAGAGCTGAAAGGGGAAAGTGATG 
TfR2 Clo F: AAATCTAGACCAGTCAAGAGCTCCTCTGC 
TfR2 Clo R: AAATCTAGATGGCTTATTGATATCAAGGTGGTT 
The complete reaction mix for every amplified 3’UTR contained 100 ng 
of genomic DNA, 1 of forward primer (10 μM), 1 μl of reverse primer 
(10μM), 2 μl of MgCl2 (25mM), 0.3 μl of Taq Gold (Roche), 5 μl of dNTP 
mix (2mM), 12.5 μl of 10X Buffer (Roche) and water to reach a final 
volume of 25 μl. Reactions were incubated in Veriti Thermal Cycler 
(Applied Biosystems, Branchberg, NJ, USA) according to the following 
program for DMT1 -IRE: an initial step at 95°C  for 10 minutes followed 
by 35 cycles at 95°C for 30 seconds, 45°C for 40 seconds, 72°C for 3 
minutes and a final elongation step at 72°C for 10 minutes. The 
amplification of the 3’UTR of TfR2 was performed according the 
following program: 95°C for 10 minutes followed by 35 cycles at 95°C 
for 30 seconds, 60°C for 35 seconds, 72°C for 35 seconds and a final 
step at 72°C for 7 minutes. 
The amplification products were visualized on 1% agarose gel (BioRad, 
Milan, Italy) and subsequently digested with restriction enzymes 
according to the following protocol: 3 μl 10X Buffer 2 (New England 
Biolabs), 0.8 μl XbaI (20.000 U/ml) (New England Biolabs), and water 
Materials and Methods 
 
 
- 53 - 
 
to reach the final volume of 30 μl. The digestion was carried on for 4 
hours at 37°C and then enzymes were inactivated at 65°C for  20 
minutes. 
Vector preparation 
2000 ng of pRL-TK vector (Promega, Madison, WI, USA) were digested 
using 3 μl Buffer 2 (10X) (New England Biolabs), 0.8 μl XbaI (20.000 
U/ml) (New England Biolabs) and water to reach the final volume of 30 
μl. The digestion was carried on for 4 hour at 37°C and then enzymes 
were inactivated at 65°C for  20 minutes. Subsequently, 1000 ng of 
digested vector were dephosporilated at the 5’ end using 3μl of NEB 
buffer Antarctic phosphatase (10X), 1μl of Antarctic phosphatase (New 
England Biolabs) and water to reach the final volume of 30 μl. The 
reaction was incubated at 37°C for 2 hours and then the enzyme was 
inactivated for 20 minutes at 65°C. The digested an dephosporilated 
vector, was finally purified from agarose gel (1%) (BioRad, Milan,Italy) 
using QuiaQuik gel extraction Kit (Quiagen). 
 
9. Quantitative real-time PCR 
Quantitative RT-PCR (qRT-PCR) was performed using the SYBRgreen 
method following standard protocols with an Applied Biosystems ABI 
PRISM 7900HT Sequence Detection system. Relative gene expression 
was calculated using the 2(-ΔCt) method, where Δt indicates the 
differences in the mean Ct between selected genes and the internal 
control. The β-actin genes was the internal controls for each gene. Mean 
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fold-change was calculated using the 2-(average ΔΔCt) method (Livak KJ et 
al., 2001), where ΔΔCt is the mean difference in the ΔCt between the 
genes and the internal control. QRT-PCR primers for each gene were 
designed using Primer Express software version 2.0 (Applied 
Biosystems). Primer sequences are the following: 
DMT1 –IRE F: TGTCCTTCCTGGACTGTGGG 
DMT1 –IRE R: CGTCCATGGTGTTCAGAAGATAGA 
TfR2 F: GCATAATGCGGGTGGAGTTC 
TfR2 R: GGCCCATGAAGATGTGGC 
β-Act F: CGTGCTGCTGACCGA 
β-Act R: GAAGGTCTCAAACATGATCTGGGT 
The significance of the gene expression differences were determined 
using the Student’s t-test; statistical significance was established at 
P<0.05. All statistical analysis was performed by Excel included in 
Microsoft Office 2007. 
 
10. Western blotting 
35 μg total lysates were loaded onto 12% polyacrylamide gels to 
evaluate the protein expression of DMT1 -IRE, onto a 10% 
polyacrylamide gels to evaluate the xpression of TfR2. Both gels were 
blotted onto polyvinylidene difluoride membranes (BioRad, Milan, Italy). 
The membranes were then incubated with a with a polyclonal rabbit 
anti-DMT1 -IRE antibody (Alpha Diagnostic) (1:500), a polyclonal rabbit 
anti-TfR2 antibody (Abcam) (1:500) and Anti-β-actin (Sigma) (1:1000) 
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was used as controls for equal loading of total lysates. The bands were 
quantified by densitometry to obtain optical densities (ODs) which were 
then normalized with respect to the normalized protein OD. We used 
the GS-800 Calibrated Densitometer and the Quantity One 4.6.3 
program (BioRad, Milan, Italy) for densitometric analyses. The 
significance of protein expression differences were determined using the 
Student’s t-test. Statistical significance was established at P<0.05.  
All the antibody used to carry out all the others reported western 
blotting are mentioned in Table 2. 
 
Table 2. List of the used antibodies. 
 
11. Site direct Mutagenesis 
The site-directed mutagenesis of the miR-Let-7d binding site of DMT1 -
IRE and  the miR-221 binding site of TfR2 were generated according to 
the manufacturer’s protocol of the QuikChange site-directed 
mutagenesis kit (Stratagene, La Jolla, CA, USA). The following primers 
were used for the mutagenesis (only the sense sequences are given, 
with the mutated nucleotides within the consensus sequence underlined 
and the site of deletion specified):  
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miR-Let-7d-Mut: 
CCTAGGAACACGAATTAGATTGCATAGTTTTAG 
miR-221-Mut: 
CTGTGTTCGTTAGGCAACCGATCCATTGTCTGCTGGGTTTCAGG 
miR-221-Del:  
CTGTGTTCGTTAGGCAACA[del]ACATTGTCTGCTGGGTTTCAGGC 
 
12. Cell transfections and luciferase assays 
To evaluate the activity of miR-Let-7d on the repression of the full-
length luciferase 3’-UTR constructs, the pcDNA3.1 miR-Let-7d construct 
(0.5 μg) and the pRL-TK 3’-UTR DMT1 -IRE target construct (0.1 μg) 
were cotransfected into K562 and HEL cells, using the TransFectin Lipid 
Reagent (BioRad, Milan, Italy) with a pGL3 CMV firefly luciferase vector 
for normalization. To evaluate the activity of both miR-221 and miR-222 
on the repression of the full-length luciferase 3’-UTR constructs, the 
pcDNA3.1 miR-221 (0.5 μg) and the pcDNA3.1 miR-222 (0.5 μg) 
constructs  and the pRL-TK 3’-UTR  TfR2 target construct (0.1 μg) were 
cotransfected into HEK 293 cells, using the TransFectin Lipid Reagent 
(BioRad, Milan, Italy) with a pGL3 CMV firefly luciferase vector for 
normalization. Luciferase activities were analyzed using a Dual 
Luciferase Reporter Assay system (Promega, Madison, WI, USA). 
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13. Mithocondrial Purification 
The mitochondrial extraction was performed using Mithocondrial 
Isolation Kit for Coltured Cells (Pierce, Rockford, IL), according to the 
manufacturer’s procedures from treated and untreated SH-SY5Y cells. 
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Results 
 
1. Evaluation of cell viability under MPP+ treatment 
Although several authors report different MPP+ concentrations to treat 
SH-SY5Y to create an in vitro model of Parkinson’s Disease, probably 
the most commonly used concentration is of 0,5 mM (Kim SY et al., 
2010).  
 
Figure 9. MTS assay on SH-SY5Y cells treated with two different concentrations of 
MPP+. Cells were treated  with 0.5 mM and 1 mM of MPP+ and their vitality was 
evaluated after 24, 48 and 72 hours from treatment (panel A). Panel B reports data in 
percentage respect to the experimental point at 0 hours from treatment. 
 
In order to evaluate the toxicity due to the use of this drug, I performed 
an MTS assay, testing two different concentrations of MPP+ after 24, 48 
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and 72 hours. As shown in Figure 9, panel A, the MPP+ treatment, 
compared with the untreated cells (CTR), reduces the viability after 24, 
48 and 72 hours from treatment, although cells keep growing. 
 
I decided to use the concentration at which cells showed a viability 
superior to 80% even after 72 hours from treatment. As shown in figure 
9, panel B, there is a very little reduction in cell viability after that time, 
for those cells treated with the final concentration of 0.5 mM of MPP+, 
while when cells were treated with a final concentration of 1 mM of 
MPP+, the viability was inferior to 80% even after 24 hours.  Because of 
these results, every other experiment performed on SH-SY5Y cells was 
carried out in 0.5 mM treatment condition. 
 
2. Expression of iron metabolism protein in treated SH-SY5Y 
I first analyzed the expression of the “basic” proteins involved in iron 
metabolism. 
Accordingly to what reported in literature (Zhang et al., 2009) about 
experiments on another PD in vitro cell system, I found no significant 
alteration in the expression of DMT1 +IRE in treated cells after 24 and 
48 hours from treatment, as shown in figure 10, panel A, and as 
confirmed by densitometric analysis shown in panel C. 
No significant variations were found for FTL protein too (figure 10, A 
and E), while FTH (figure 10, A and D) and IRP2 (figure 10, B and G) 
seem to be strongly increased in treated cells. 
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TfR1  resulted increased in a significant way after 24 and 48 hours from 
treatment (figure 10, B and F). 
 
Figura 10. Protein and mRNA levels of genes involved in iron metabolism. Experiment 
carried out on treated and untreated cells. (A) WB for DMT1 +IRE and FTH and FTL in 
treated cells; (B) WB for TfR1 and IRP2 in treated cells; (C, D, E, F, G) Densitometric 
analysis for the blotted proteins shows a significant expression increase of FTH (D), 
TfR1 (F) and IRP2 (G) (t-test; p<0.05). 
 
 
3. Expression of DMT1 –IRE and TfR2 in treated cells 
Because DMT1 –IRE and TfR2 are the main subject of this thesis, their 
expression is reported in this separate paragraph. Their expression was 
evaluated at both mRNA and protein level by Real Time-PCR and 
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Western Blot. As shown in figure 11 (A) the expression of mRNA 
encoding for Tfr2, in treated cells, is increased if compared with the 
control value. Also the analysis on the protein showed the increase. 
Data were confirmed by densitometric evaluation of the band intensity 
(figure 11, B-C). The same trend was found about the expression of 
DMT1 –IRE: figure 11 (D) shows an over-expression of mRNA encoding 
for the protein. The increase was subsequently confirmed by Western 
Blot and densitometric analysis shown in figure 11 (E-F)  
 
Figure 11. Expression of DMT1 –IRE and TfR2 in treated and untreated cells. Real 
Time-PCR shows the increase in the expression of both TfR2 and DMT1 –IRE (A, D) 
and the same is at protein level (B, E), confirmed by densitometric analysis (C, F). A 
significant increase was found for both investigated genes/proteins (t-test; p<0.05).  
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4. Bioinformatics selection of microRNAs potentially regulating 
DMT1 –IRE and TfR2 
The selection by which our group identified microRNA-Let-7d as 
targeting DMT1 –IRE (recent published paper by Andolfo et al., 2010) 
was carried out predominantly using PITA tool on the basis of the 
energy-based scores for microRNA-target interactions, ΔΔG. Several 
prediction programs have been developed to identify potential miRNA 
targets (Sethupathy P et al., 2006). Our in silico analysis using the 
mirBase targets database (version 4) (Griffiths-Jones S, 2004) was 
directed towards identification of miRNAs that can potentially target the 
DMT1-IRE. All the analysis let us identify four potential miRNAs: miR-
15a, miR-15b, miR-223 and miR-Let-7d.  
For the selection of microRNAs potentially involved in the binding of the 
3’UTR of TfR2, outputs from 3 different online prediction tools 
(MicroCosm, TargetScan and Pita tool), queried by submitting the 3’UTR 
of interest, were compared in order to reduce the list of microRNAs to 
study (I arbitrarily chose as cutoff the value -10 considering only 
microRNAs with a lower score). Lower is the score, higher is the 
probability that the microRNA is really able to interact with submitted 
RNA sequence. In order to reduce the number of microRNAs selected 
using bioinformatics methods, these results were sub-compared with 
literature data and particularly were selected those microRNAs 
expressed in general in brain derived from microarray experiment on 
human tissues published by Baskerville S et al., (2005). The list was so 
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reduced to about 20 different microRNAs (Table 3) ad of particular 
interest I obtained a short list of 5 microRNAs resulted from literature 
data and at list two different bioinformatics tools: microRNA-147 (PITA 
score = -14.24, microRNA-221 (PITA score = -18.63), microRNA-222 
(PITA score = -13.08), microRNA-200c (PITA score = -11.18) and 
microRNA-326 (PITA score = -11.33). 
 
Table 3. Bioinformatics selection of microRNAs potentially targeting the 3’UTR of 
TfR2. In red are reported all the microRNAs that resulted as the output of more then 
one used bioinformatics tool. 
 
5. Expression evaluation of selected microRNAs potentially 
targeting the 3’ UTR of the mRNA encoding for TfR2 in SH-SY5Y 
cells. 
The basal expression of the selected microRNAs was evaluated in SH-
SY5Y using Real Time-PCR carried on with stem–loop reverse 
transcriptase primer specific for every microRNA subjected to the assay. 
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The relative expression of every microRNA was obtained by the 
normalization on microRNA-RNU6. As shown in figure 12, almost all the 
microRNAs selected are very low expressed in SH-SY5Y cell line with the 
exception of microRNA-221 and microRNA-222 that on the contrary are 
very highly expressed in SH-SY5Y cells. 
 
Figure 12. Relative expression of selected microRNAs in SH-SY5Y cell line. The 
experiment was carried out on untreated cells to evaluate the basal expression of all 
the selected microRNAs. 
 
6. Expression of microRNAs in SH-SY5Y cells during the 
treatment with MPP+: searching for a “TfR2 binder”. 
I first evaluated the expression of the 5 microRNAs (microRNA-147, 
microRNA-221, microRNA-222, microRNA-200c and microRNA-326) 
that, at the bioinformatics analysis, resulted as common result of more 
then one bioinformatics tools, also supported by literature data, as 
explained before. This experiment was performed in order to evaluate 
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their trend of expression during the cell treatment. The Real Time-PCR 
was performed on retro- trascribed  microRNAs from SH-SY5Y cells 
treated with MPP+ and the relative expression was evaluated 
normalizing on the expression of microRNA-RNU6 endogenous control. 
Figure 13 (A) shows the relative basal expression of the five sub-
selected microRNAs in SH-SY5Y cell.  
 
Figure 13. Sub-selected microRNAs expression in SH-SY5Y cells during the 
treatment. (A) miR-147, miR-200c and miR-326 resulted very low expressed in 
untreated  SH-SY5Y cells. miR-221 and miR-222 were highly expressed in the same 
cells. (B, E, F) miR-147, miR-200c and miR-326 showed not consistent variations in 
their expression after 24 and 48 hours from treatment while both miR-221 and miR-
222 resulted significantly decreased after 24 and 48 hours from treatment (C, D) (t-
test; p<0.05).  
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As shown, the expression of both microRNA-221 and microRNA-222 is 
very high when compared with the other studied microRNAs. In fact, 
the expression of microRNA-147,  microRNA-200c and microRNA-326 is 
very low and quite near the zero in SH-SY5Y cell line.  
Anyway I decided to evaluate to analyze the expression of all the five 
sub selected microRNAs during the the treatment, after 24 and 48 
hours to better understand if the MPP+ treatment could induce 
variations in their expression levels. Moreover, I was very confident in 
microRNA-147 because it was the only one microRNA, predicted with a 
good score as the potential microRNA targeting TfR2 by all the three 
queried bioinformatics tools. The relative expression of the mentioned 
microRNAs is reported in figure 13 (panels B-F). MicroRNAs -147, -200c 
and -326 showed a no specific trend during the treatment and moreover 
the low reduction observable after 24 hour from treatment with MPP+ 
results not significant (t-test) (figure 13, B, E and F). 
On the contrary, the expression levels in SH-SY5Y cells for microRNA-
221 and microRNA-222 show a trend in reduction after 24 and 48 hours 
from MPP+ treatment. The reduction resulted significant already after 24 
hours from treatment (figure 13, C and D) and it is maintained after 48 
hours. Being TfR2 over-expressed in SH-SY5Y cells treated with MPP+  
at both mRNA and protein level (figure 11, A), I was searching for a 
microRNA potentially targeting it, so showing an opposite trend (figure 
14). For these reasons, the best candidate for the subsequent studies 
were microRNA-221 and microRNA-222. 
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Figure 14. Opposite trend of expression between TfR2 and microRNA-221/microRNA-
222. This trend suggests a potential expression regulation of TfR2 mediated by 
microRNA-221 and microRNA-222. Panel A shows the TfR2 mRNA increase after 24 
and 48 hours from treatment while panel B shows the microRNAs reduction in the 
same experimental points. 
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7. Expression of microRNA-Let-7d in SH-SY5Y cells during the 
treatment with MPP+. 
As explained before, the activity of microRNA-Let-7d in the expression 
regulation on DMT1 –IRE was recently published by our group (Andolfo 
et al., 2010). Being DMT1 –IRE up-regulated during the treatment with 
MPP+ in my PD in vitro model (figure 11,D-F), I enquired if the same 
regulation mechanism could be active in this different cell system. The 
first step to answer this question was the evaluation of the microRNA-
Let-7d expression in SH-SH5Y cells and, moreover, if it resulted altered 
in its expression in SH-SY5Y cells treated with MPP+.  
The Real Time-PCR was performed on retro-transcribed microRNA-Let-
7d from SH-SY5Y cells treated with MPP+ and the relative expression 
was evaluated normalizing on the expression of microRNA-RNU6 
endogenous control. As shown in figure 15 (B), microRNA-Let-7d levels 
resulted strongly and significantly reduced in treated cells after 24 and 
48 hours from treatment. Also in this case is possible to observe an 
opposite trend in the expression of DMT1 –IRE (figure 15, A) respect to 
the expression of the considered microRNA. 
This data suggest not only the fact that microRNA-Let-7d is expressed 
in SH-SY5Y cells but also suggest it potential effect on the regulation of 
DMT1 –IRE in my in vitro PD model. 
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Figure 15. Opposite trend of expression between DMT1 -IRE and microRNA-Let-7d. 
This trend suggests a potential expression regulation of DMT1-IRE mediated by 
microRNA-Let-7d. Panel A shows the DMT1 -IRE mRNA increase after 24 and 48 hours 
from treatment while panel B shows the microRNA reduction in the same experimental 
points. 
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8. Evaluation of the binding between microRNA-221 and 
microRNA-222 and the 3’UTR of mRNA encoding for TfR2 and 
the binding between microRNA-Let-7d and the 3’UTR of the 
mRNA encoding for DMT1 –IRE 
To verify the bioinformatics predictions, a renilla luciferase reporter 
vector was constructed that contained the full-length 3’-UTR of human 
DMT1-IRE mRNA, the expression of which was driven by the thymidine 
kinase (Tk) promoter (Tk-ren/DMT1-IRE). Pre-miR-Let- 7d was cloned 
into a mammalian expressing vector (pcDNA3.1). The reporter construct 
(Tk-ren/DMT1-IRE) and miR-Let-7d were co-transfected in K562 cells, 
with the pGL3-CMV-firefly luciferase vector to normalize for transfection 
efficiency.  
 
 
Figure 16. Luciferase assay to evaluate the binding between DMT1 –IRE 3’UTR and 
microRNA-Let-7d. K562 cells transfected with the construct expressing microRNA-Let-
7d showed a significant reduction of the luciferase activity (t-test; p<0.05). 
 
 
Interestingly, the relative luciferase activity was markedly decreased 
(about -70%) in cells co-transfected with the Tk-ren/DMT1-IRE 
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construct and miR-Let-7d (P<0.05) which indicates miR-Let-7d binding 
to the 3’-UTR of the DMT1-IRE, resulting in decreasing luciferase protein 
expression (Figure 16). 
A similar experiment was planned to test the binding between 
microRNA-221 and microRNA-222 with the 3’UTR of the mRNA encoding 
for TfR2. A renilla luciferase reporter vector was constructed, containing 
the full-length 3’-UTR of human TfR2 mRNA, the expression of which 
was driven by the thymidine kinase (Tk) promoter (Tk-ren/3’UTR TfR2). 
Pre-miR-Let-221 and pre-miR-222 were cloned into a mammalian 
expressing vector (pcDNA3.1). The reporter construct (Tk-ren/3’ UTR 
TfR2) and pre-miR-221  were co-transfected in HEK293 cells, with the 
pGL3-CMV-firefly luciferase vector to normalize for transfection 
efficiency. The same co-transfection (using Tk-ren/3’ UTR TfR2 and the 
construct containing pre-miR-222)  was carried out to test also the 
ability binding the studied 3’UTR by pre-miR-222.  
As shown in figure 17 (A), the relative luciferase activity was strongly 
decreased (-70%) in cells co-transfected with the Tk-ren/3’UTR TfR2 
construct and miR-221 (P<0.05) which indicates miR-221 is really able 
to bind the 3’-UTR of the mRNA encoding for TfR2, resulting in a 
decreased luciferase protein expression.  
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Figure 17. Luciferase assay to evaluate the binding between TfR2  3’UTR and 
microRNA-221/microRNA-222. (A) HEK293 cells transfected with the construct 
expressing microRNA-221 showed a significant reduction of the luciferase activity (t-
test; p<0.05). (B) HEK293 cells transfected with the construct expressing microRNA-
222 showed no alterations of the luciferase signal, suggesting that microRNA-222 is 
not able to bind the 3’UTR of TfR2. 
 
As concerns the luciferase assay referred to the study of microRNA-222,  
since the luciferase signal in those cells transfected with the construct 
containing the microRNA is comparable to the luciferase signal of those 
cells transfected with the control vector, this suggests that microRNA-
222 is not able to bind the 3’UTR of the mRNA encoding for TfR2 cloned 
at the 3’ end of the renilla luciferase gene. The lack of this binding 
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prevent the regulation of renilla luciferase expression and the final 
effect is the same production of the protein figure 17 (B).  
This data allowed me to exclude microRNA-222 from the subsequent 
studies since it is not a potential “regulator” of TfR2. On the contrary, 
microRNA-221 could be involved in such regulation.  
 
9. Mutagenesis of microRNA-let-7d and microRNA-221 
 
 
 
Figure 18. Mutagenesis design. Three point mutation (shown in bolt) were introduced 
in pre-microRNA-221 cloned into the pcDNA3.1 expression vector and in the other 
construct were removed three bases (reported in transparency). In pre-microRNA-Let-
7d cloned in the same vector, five point mutations were introduced (shown in bolt). 
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MicroRNA-221 cloned into the pcDNA3.1 vector was mutagenized by 
introducing point mutations and deletion in the region that better binds 
the 3’UTR of the mRNA encoding for TfR2, localized in its 5’UTR. A first 
construct was created introducing three point mutations in alternating 
positions while the deleted one was created removing three consecutive 
bases as shown in figure 18. MicroRNA-Let-7d was mutagenized 
introducing 5 poin mutations in the region that better matchs with the 
3’UTR of DMT1 –IRE as shown in figure 18 (bottom). 
 
 
10. Mutagenized microRNAs restore the luciferase activity in 
transfected cells. 
Luciferase assay was repeated in  K562 cells tranfected with wild-type 
(WT) and mutated microRNA-Let-7d. Also in this case when cells were 
transfected with the WT microRNA, le luciferase activity resulted 
decreased. On the contrary, when cells were transfected with the 
mutated microRNA, the luciferase signal was restored (figure 19). These 
data confirm that microRNA-Let-7d is really able to bind the DMT1 –IRE 
3’UTR repressing luciferase expression. In fact, when the cells are 
transfected, the expressed mutated microRNA is no more able to bind 
the co-transfected vector containing the 3’UTR, and the lack of the 
binding inhibits the degradation of the mRNA encoding for the 
luciferase, restoring the complete signal (figure 19). 
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Figure 19. Luciferase assay with the mutagenized microRNA-Let-7d. K562 cells 
transfected with the mutated form of microRNA-Let-7d showed a complete restore of 
the luciferase signal when compared with cells transfected with the WT form of 
microRNA-Let-7d (t-test; p<0.05). 
 
 
In regards to the study of microRNA-221 and the 3’UTR of TfR2, the 
repeated luciferase assay, also in this case shows that when HEK293 
cells were transfected with the WT microRNA, the luciferase activity 
resulted decreased. On the contrary, when cells were transfected with 
the mutated microRNA, both for point mutations and deletion, the 
luciferase signal was restored (figure 20). The transfection with WT 
construct gave a significant reduction again. Both constructs, containing 
the point mutated and deleted forms of microRNA-221 loss the ability to 
bind the 3’UTR of the mRNA encoding for TfR2 and this causes their 
inability to negatively “regulate” the protein expression, so the 
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luciferase activity was reinstated confirming the potential regulation 
activity due to microRNA-221. 
 
Figure 20. Luciferase assay with the mutagenized microRNA-221. HEK293 cells 
transfected with both the mutated forms of microRNA-221 showed a complete restore 
of the luciferase signal when compared with cells transfected with the WT form of 
microRNA-221 (t-test; p<0.05). 
 
 
11. Activity of microRNA-Let-7d and microRNA-221 on 
endogenous targets. 
To evaluate if the studied microRNAs were able to function on their 
respectively endogenous targets, they were transfected in SH-SY5Y 
cells treated with MPP+ and their targets were evaluated at both mRNA 
and protein level. In fact, as shown in figure 21, when cells are 
tranfected with the wild type microRNA-Let-7d, this results in a 
reduction in the expression of both mRNA encoding for DMT1 –IRE and 
the same is analyzing the protein expression. 
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Figure 21. : Expression of DMT1 –IRE in transiently transfected cells with WT and 
mutated microRNA-Let-7d after 0, 24 and 48 hours from treatment with MPP+.  In the 
upper part of the image is reported the mRNA expression level. The increasing trend 
in the expression of DMT1 –IRE is maintained after 24 and 48 hours from treatment 
but in those experimental points in which an over-expression of microRNA-Let-7d was 
induced, the mRNA level decreased if compared with control cells and with cells 
transfected with the mutated microRNA (t-test; p<0.05) and the same happened at 
protein level (WB in the bottom). 
 
Even in this case, the up-regulated trend in DMT -1 expression after 0, 
24 and 48 hours from treatment with MPP+ is maintained and when 
cells are transfected with the mutated construct, the ability of 
microRNA-Let-7d to bind the 3’UTR of DMT1 –IRE is lost and this causes 
the lack of the regulation of DMT1 –IRE expression and there is the 
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restore in the production of mRNA encoding for DMT1 –IRE and its 
corresponding protein. 
Concerning to the experiment performed on the same cell system to 
evaluate the ability of microRNA-221 to reduce the expression of TfR2, 
also in this case, the cells transiently transfected with the construct in 
which the wild type microRNA was cloned, showed a reduction in both 
mRNA encoding for TfR2 and in the corresponding protein too.  
 
 
Figure 22. Expression of TfR2  in transiently transfected cells with WT and mutated 
microRNA-221 after 0, 24 and 48 hours from treatment with MPP+. In the upper part 
of the image is reported the mRNA expression level. The increasing trend in the 
expression of TfR2 is maintained after 24 and 48 hours from treatment but in those 
experimental points in which an over-expression of microRNA-221 was induced, the 
mRNA level decreased if compared with control cells and with cells transfected with 
the mutated microRNAs (t-test; p<0.05) and the same happened at protein level (WB 
in the bottom). Only the construct containing point mutations in pre-microRNA-221 
was tested in the WB experiment. 
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Even in this case the up-regulation trend in the expression of TfR2 is 
conserved after 0, 24 and 48 hours from treatment with the drug and 
when cells were transfected with both mutated and deleted microRNA-
221, the lack in the binding with the 3’UTR of the mRNA encoding for 
TfR2 causes the restore in the production of TfR2.  
Because luciferase assay (figure 20) and Real Time-PCR on SH-SY5Y 
treated cells (figure 22, upper part) showed that both the mutated 
constructs were able to work and both losed the ability to bind the 
target 3’UTR, only the one containing point mutations was tested for 
Western Blot analysis. 
 
According to these preliminary data, both microRNA-Let-7d and 
microRNA-221 are really able to regulate the expression of the 
respectively genes/proteins involved in iron metabolism, DMT1 –IRE 
and TfR2 by binding the 3’UTR of their mRNA. Probably their activity 
mediates the degradation of the mRNAs, since the effect of the 
microRNAs are already observed at mRNA level and subsequently at 
protein level. 
 
12. Mithocondrial expression of TfR2 in SH-SY5Y cells treated 
with MPP+ 
Mithocondria from SH-SY5Y cells treated with MPP+ at 0, 24 and 48 
hours were purified in order to evaluate the expression of TfR2 on 
mithocondrial membranes. On the contrary of what reported in 
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literature (Mastroberardino et al., 2009), as shown in figure 23, I found 
no over-expression of TfR2 in mithocondria but instead a not significant 
reduction is slightly detectable. Moreover, a perfect purification of the 
above mentioned organelles is very difficult to obtain in laboratory. This 
supports the idea that probably that result is due to potential 
contaminations of the used samples and that probably TfR2 is 
completely absent on mithocondrial cell membranes. 
 
 
Figure 23. Mithocondrial expression of TfR2 in SH-SY5Y cells treated with MPP+. 
Although is seems there is a consistent reduction in the mithocondrial expression of 
TfR2 after 48 hours from treatment, it resulted not significant at the t-test, suggesting 
no alteration in protein expression during the treatment. 
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Discussion 
 
Dopaminergic cell death in the substantia nigra is central to Parkinson’s 
disease (PD) but the neurodegenerative mechanisms have not been 
completely elucidated. The normal substantia nigra has a higher 
concentration of iron than the liver, which is the body's main iron store 
(Gotz ME et al., 2004). Iron accumulation in dopaminergic neurons and 
glial cells in the substantia nigra of PD patients may contribute to the 
generation of oxidative stress, protein aggregation and neuronal death. 
However, the mechanisms involved in iron accumulation remains 
unclear. Moreover, literature is very rich in contradictions about iron 
metabolism in Parkinson’s Disease and this make the study of PD very 
complex. For example, a recent study shows the down-regulation of 
DMT1 –IRE and the up-regulation of DMT1 +IRE (Salaza J et al., 2008), 
a genomic study failed to show DMT1 (in general, so not referred to a 
specific isoform) up-regulation in an M9D dopaminergic cell line treated 
with MPP+ (Wang J et al., 2007) and another recent study using 
MES23.5 dopaminergic cells shows that MPP+ treatment is sufficient to 
increase DMT1 -IRE expression increasing iron uptake because of a 
major iron influx (Zhang S et al., 2009). About TfR2 in Parkinson’s 
Disease literature shows even less information. In fact, the first 
demonstration that TfR2 is up-regulated in PD dates back to 2009 when 
Mastroberardino et al. (2009) not only found an increase of TfR2 in 
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dopaminergic neurons in PD but even suggests a novel transferrin/TfR2-
mediated mitochondrial iron transport system disrupted in Parkinson's 
Disease proposing TfR2 as directly involved in the mithocondrial iron 
uptake because of  the presence of a particular aminoacidic sequence 
able to target the protein in mithocondrial membranes.   
Tightly regulated iron homeostasis is essential for maintenance of life in 
eukaryotic organisms. Stable plasma concentrations and adequate 
levels of cellular iron are maintained through a balance of multiple 
processes that regulate its absorption, transport, storage and recycling 
(Andrews NC, 2008; De Domenico I et al., 2008). DMT1 has a crucial 
role in this iron homeostasis because it is an H+/divalent metal 
symporter that is involved in intestinal non-heme iron uptake, as well as 
in the peripheral iron cycle, as seen in erythroblasts (Iolascon A et al., 
2009; Gruenheid S et al., 1995; Gunshin H et al., 1997). DMT1 
expression is finely regulated by different mechanisms. One involves 
the iron-responsive element (+IRE) in the 3’-UTR of the DMT1 +IRE 
which can alter mRNA stability according to iron status (Tabuchi M et 
al., 2002; Galy B et al., 2008; Gunshin H et al., 1997). The other 
isoform, DMT1 –IRE is characterized by the absence of the element 
(+IRE) in its mRNA 3’UTR so the regulation of its expression is not 
modulated by the iron concentration into the cells and it is not mediated 
by Iron Regulative Proteins (IRPs). For these reasons other regulative 
mechanisms are hypothesized. We recently suggested a novel 
mechanism of regulation that involves microRNA-Let-7d and we proved 
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that in erythroid cells. Particularly, we found that that in erythroid cells, 
DMT1-IRE expression is under the regulation of microRNA-Let-7d. 
DMT1-IRE and miR-Let-7d are inversely correlated with CD34(+) cells, 
K562 and HEL cells during erythroid differentiation. Moreover, over-
expression of miR-Let-7d decreases the expression of DMT1-IRE at the 
mRNA and protein levels in K562 and HEL cells. MiR-Let-7d impairs 
erythroid differentiation of K562 cells by accumulation of iron in the 
endosomes (Andolfo I et al., 2010). As explained in another section, 
microRNAs are now well recognized as important post-transcriptional 
regulators of gene expression. Their mechanisms of action have been 
intensively studied more recently, and their effects are known to be 
exerted primarily through suppression of mRNA translation or by 
promotion of the physical destruction of mRNA after the microRNA 
hybridizes with the 3’-UTR of their mRNA target(s).  The first purpose of 
this study was to validate the activity of microRNA-Let-7d in the 
regulation of DMT –IRE in an in vitro model of Parkisnon’s Disease. Here 
I showed that DMT1 –IRE is up-regulated in SH-SY5Y cells treated with 
MPP+. This trend of expression is opposite to that of miR-Let-7d, a 
putative regulator of DMT1-IRE. In this context, I first examined 
whether miR-Let-7d can mediate the repression of a luciferase/DMT1-
IRE 3'-UTR reporter construct in K562. Interestingly, miR-Let-7d 
produced a 60% decrease in the luciferase activity, indicating that it 
binds to the 3’-UTR of the DMT1-IRE mRNA and decreases the luciferase 
protein translation. Then I evaluated the regulation of DMT1 -IRE after 
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over-expression of miR-Let-7d. Here, I have shown that the 
endogenous DMT1-IRE is down-regulated by miR-Let-7d in my in vitro 
model of Pakinson’s Disease, at the mRNA levels, as previously 
described for other members of the miR-Let-7 family (Roush S et 
al.,2008), and subsequently at protein levels. When cells were  
transiently transfected with the mutated microRNA-Let-7d, this cause 
the lack of the binding between the microRNA and its target and the 
DMT1 –IRE endogenous expression was restored at a level comparable 
to the control one suggesting that microRNA-Let-7d is no more able to 
regulate DMT1 –IRE expression.  
A similar remark is for Transferrin Receptor type 2. Transferrin 
receptors are carrier proteins for transferrin. They are needed for the 
import of iron into the cells and import iron by internalizing the 
transferrin-iron complex through receptor-mediated endocytosis. TfR2 
shares about 45% homology with TfR1, but its function in iron 
homeostasis remains elusive (Kawabata et al., 1999). As reported 
before, differently for what happens in the regulation of the quite 
ubiquitously expressed Transferrin Receptor type 1 (TfR1), TfR2 can not 
be regulated by IRPs because of the lack on the IRE elements at the 
3’UTR of its mRNA. For this reason, also in this case a different 
regulation mechanism can be supposed.  The second aim of this study 
was firstly to verify the potential activity of microRNA-221 to function as 
a “TfR2 regulator” and then to verify its regulation in Parkinson’s 
Disease using SH-SY5Y cell line treated with MPP+.  
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Here I showed that TfR2 is up-regulated in SH-SY5Y cells treated with 
MPP+. This trend of expression is the opposite to that of microRNA-221, 
the microRNA that I a selected as a putative regulator of TfR2. In this 
context, I first examined whether microRNA-221 can mediate the 
repression of a luciferase/TfR2 3'-UTR reporter construct in HEK293. 
Interestingly, miR-221 produced a 70% decrease in the luciferase 
activity, indicating that it binds to the 3’-UTR of the TfR2 mRNA and 
decreases the luciferase protein translation. Then I evaluated the 
regulation of TfR2 after over-expression of microRNA 221. Here, I have 
shown that the endogenous TfR2 is down-regulated by miR-Let-7d in 
the studied in vitro model of Pakinson’s Disease, at both mRNA level 
and protein level.  
Another unanswered question is if the iron-overload in PD is to be 
ascribed to DMT-1 or TfRs. Also in this case unclear literature data are 
reported as discussed elsewhere. For example, while Mastroberardino et 
al. (2009) tries to attribute the iron excess in dopaminergic neurons in 
PD to TfR2, Hirsch (2009) attributes the iron overload as due to the 
excluded a role of transferrin and its receptor in iron accumulation.  
According to what I found in my cellular model, a synergic action of 
both TfR2 and DMT1 –IRE can be suggested. Both proteins resulted 
increased in SH-SY5Y cells and no contradiction can be seen in these 
findings following this proposed model: TfR2 increases and it is involved 
in iron cellular uptake. The fact that I found no TfR2 increase on 
mithocondrial surface (in contrast with what reported by 
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Mastroberardino et al., 2009) suggests that probably the over-
expression is on cell membrane, and this could justify the excess of iron 
influx. The complex Tf/TfR2 let the iron enter the cell by endocytosis 
(figure 24). It is well known that the subsequent acidification of the 
endosome causes the release of iron from Transferrin and it is also well 
known that DMT1 –IRE is the direct liable protein involved in the 
transport of iron from the endosome to the inner cellular compartment 
(as widely discussed in the introduction session). Here, I also found the 
over-expression of DMT1 -IRE and this is consistent with the presence 
of a great quantity of iron into the cell (figure 24). Probably the up-
regulation of only one of the studied proteins, would not be sufficient to 
justify the excess of iron influx. It would be expected that, under 
condition of cellular iron overload, iron import machinery would be post-
transcriptionally regulated. As shown here, likely the regulation of both 
DMT1 –IRE and TfR2 is mediated by microRNAs (respectively microRNA-
Let-7d and microRNA-221). The activity of the studied microRNAs is 
carried out in terms of mRNA degradation rather than in blocking of the 
translation since the reduction of the expression is already found at 
mRNA levels and confirmed at protein levels. 
As explained, DMT1 –IRE and TfR2 expressions are not regulated by 
intracellular iron levels and their levels remain elevated even in case of 
marked cellular iron overload. Moreover, I also found the increase in the 
expression of TfR1 in treated cells. The concurrent over expression of 
TfR1, TfR2 and DMT1 –IRE could leads to their cooperation in 
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supporting iron cellular influx and this could justify the amount of iron in 
substantia nigra from PD affected patients, promoting iron toxicity 
(figure 24). This condition could be aggravated by the impairment of 
iron export. In fact, recent observations  show that tau-knockout mice 
develop age-dependent brain atrophy, iron accumulation and substantia 
nigra neuronal loss, with concomitant cognitive deficits and 
parkinsonism. Amyloid precursor protein (APP) ferroxidase activity 
couples with surface ferroportin to export iron, but its activity is 
inhibited in Alzheimer’s and Parkinson’s diseases, thereby causing 
neuronal accumulation. In primary neuronal colture, it was found that a 
loss of tau also causes iron retention, by decreasaing surface trafficking 
of APP (Lei P et al., 2012).   
 
The importance of the preliminary data reported here can be supported 
by the observation that, therapeutically targeting these pathways 
therefore may be a novel therapeutic avenue that obviates the need for 
systemic iron chelation that often results is very severe side effects. In 
fact, blocking  one or both studied microRNAs, this could lead to a 
reduction in  dopaminergic neurons iron uptake in PD affected patients. 
Moreover this study could be the first important answer to the question: 
“How TfR2 expression is regulated if it is surely not regulated by IRPs 
on the contrary of what happens for TfR1?”. 
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Figure 24. Model of iron overload in PD. Panel A shows what happens in normal 
condition while in a cellular model of PD (panel B) a low expression of microRNA-221 
and microRNA-Let-7d was found. This phenomenon causes the up-regulation of both 
DMT1 –IRE and TfR2. An increase in the expression TfR1 was also found. All the three 
mentioned proteins are involved in iron uptake endosome mediated. Moreover, recent 
evidences show that in PD the iron export activity of FPN1 is reduced. All these factors 
contribute to the iron accumulation and to its subsequent toxicity. 
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Anyway further studies are necessary to confirm these data. Several 
other studies have been planned, such as the in vitro inhibition of the 
endogenous studied microRNAs and the validation on other PD in vitro 
models. Concerning to the use of animal models, an idea could be to 
create the commonly used in vivo model of PD treating mice with MPTP 
(the MPP+ precursor) and to evaluate the microRNA-Let-7d and 
microRNA-221 expression after the treatment in their substantia nigra.  
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